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1 Abstract 
1.1 Abstract 
Glioblastoma multiforme belongs to the group of gliomas and represents the most 
malignant entity of all primary brain tumors in adults. Despite recent diagnostic and 
therapeutic achievements the glioblastoma has the poorest prognosis of all 
primary brain tumors. Improving the initial diagnosis and the assessment of 
response to treatment in malignant gliomas, while avoiding invasive methods as 
much as justifiable, is one major aspect actual research is focusing on. Imaging 
studies are used to calculate tumor volume and to define vital, necrotic and cystic 
areas within a tumor. Since the subjective, visual interpretation of MRI is based on 
qualitative observation of variation in signal intensity, a correlation of signal 
intensities with histological features of a tumor in this manner is not possible. The 
need for an objective method for the reliable description of a tumor and the 
interpretation of follow-up studies in single patients and their collective was the 
inspiration to the concept of the present study. 
In the proposed work histograms of signal intensities from delineated areas in MRI 
scans served as a method of quantitative data acquisition. Using the image 
analysis software DoctorEye, tumors and other pathologic tissues as necrosis or 
edema could easily be rendered, while at the same time histograms of the signal 
intensities within a tumor, as well as mean and median signal intensities were 
calculated. Additionally this technique enabled us to precisely calculate the 
volumes of the different investigated tissues (active tumor, necrosis and edema) 
and to assess their development during the course of disease. To the best of my 
knowledge there was no data available that uses histograms of signal intensities of 
MRI for the characterization of glioblastoma, when the proposed study was 
initiated. 
In total more than 22.000 DICOM-files based on routine-MRI scans, from 33 
anonymized patients suffering from suspected glioblastoma, have been analyzed. 
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These data included T1, T1 with gadolinium contrast enhancement, T2 and T2-
Flair sequences, representing another novelty, as in the common criteria most 
often only the assessment of the T1 with gadolinium contrast enhancement 
sequence in MR images is suggested. The data of the histograms were uploaded 
to Microsoft Office Excel 2007, to perform further statistics, including the 
normalization of the data. In addition to the comparison of the distribution of the 
signal intensities, focus was laid on the calculation and interpretation of the 
respective maximum values and the average signal intensities of the histograms 
and their development over time. In nine of the 33 patients a complete follow-up 
could be analyzed, referring to DICOM data-sets at diagnosis, after surgery and 
after radio- and chemotherapy. 
Since the histograms of the different pathologic tissues vary in all sequences, the 
measurement of volumes and the segmentation of the tumor in the various MR 
sequences offer an optimal way to objectively distinguish between active tumor 
tissue, necrosis and edema. At the time of diagnosis the histogram of all 
glioblastoma showed a bimodal distribution of signal intensities in the T1 with 
gadolinium contrast enhancement sequence. Such similarities of the graphical 
shape are seen during follow-up in individual patients as well. 
It can be assumed that by using combinations of histograms from different 
sequences the tumor can be described in a much better way than by calculating 
solely the tumor volume. With the proposed method one can define necrotic areas 
and active tumor, and simultaneously calculate their volume for any point of time. 
By standardizing the average signal intensity, relatively to the signal intensities of 
the corresponding cerebrospinal fluid, it was possible to demonstrate a clear 
difference between tumor and necrosis at different points of time and in different 
sequences. The results of the present study lead to the conclusion that the use of 
these histograms is an innovative way to gain new, tumor-specific information, 
without performing additional examinations on the patient. This method can be a 
complementary diagnostic tool to distinguish between different intracranial lesions, 
and to assess the response to treatment of glioblastoma or its progression. 
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Nevertheless, a standardized method for image acquisition is needed to apply this 
method center-independent and to achieve a higher comparability between the 
results. Furthermore, the proposed segmentation algorithm too time consuming to 
be applied in routine clinical practice. If these restrictions will be resolved, this 
method can constitute a simple, effective tool for the diagnosis, the assessment of 
individual and collective courses of disease and the modeling of tumor growth and 
response to treatment. 
1.2 Zusammenfassung 
Eine innovative mathematische Analyse von Routine-MRT-Bildern bei 
Patienten mit Glioblastom mithilfe von DoctorEye 
Das Glioblastom gehört zu der Gruppe der Gliome und stellt die häufigste Entität 
aller primären Gehirntumoren im Erwachsenenalter dar. Trotz jüngster 
diagnostischer und therapeutischer Errungenschaften hat das Glioblastom immer 
noch die schlechteste Prognose aller primären Hirntumoren. Die Verbesserung 
der Erstdiagnose und die Beurteilung des Ansprechens auf die Behandlung von 
malignen Gliomen, bei gleichzeitiger, vertretbarer Vermeidung invasiver 
Methoden, ist ein wichtiger Aspekt auf den sich die aktuelle Forschung 
konzentriert. Bildgebende Verfahren werden verwendet, um Tumor-Volumina zu 
berechnen und um zwischen vitalen, nekrotischen und zystischen Tumorarealen 
zu unterscheiden. Da die subjektive, visuelle Interpretation von MRT-Bildern auf 
einer qualitativen Beobachtung von Variationen der Signalintensität basiert, ist 
eine Korrelation von Signalintensitäten mit histologischen Merkmalen eines 
Tumors auf diesem Wege nicht möglich. Der Mangel an objektivierbaren 
Methoden zur zuverlässigen Beschreibung von Tumoren und der Interpretation 
der Follow-up Studien von einzelnen Patienten und deren Kollektiv war Inspiration 
zu dem Konzept der vorgestellten Studie. 
In der vorliegenden Arbeit wurden Histogramme von Signalintensitäten 
umschriebener Areale in MRT Abbildungen als ein Verfahren zur quantitativen 
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Datenerhebung verwendet. Mithilfe der Bildbearbeitungssoftware DoctorEye 
konnten Tumoren und andere patholgische Gewebeveränderungen, wie Ödeme 
und Nekrosen, benutzerfreundlich segmentiert und gleichzeitig Histogramme der 
Signalintensitäten innerhalb eines Tumors, sowie mittlere und mediane 
Signalintensitäten berechnet werden. Zusätzlich war es möglich mit diesem 
Verfahren genaue Volumina der einzelnen Gewebetypen (aktiver Tumor, Nekrose 
und Ödem) zu bestimmen und deren Entwicklung im Krankheitsverlauf zu 
beurteilen. Nach meinem Kenntnisstand gab es zu dem Zeitpunkt, als die 
vorliegende Studie initiiert wurde, keine vergleichbaren Daten, die Histogramme 
der Signalintensitäten von MRTs verwendeten, um Glioblastome zu 
charakterisieren. 
Insgesamt wurden über 22.000 DICOM-Dateien, basierend auf Routine-MRT-
Bildern von 33 anonymisierten Patienten mit histologisch gesichertem oder 
bildmorphologisch verdächtigem Glioblastom, bearbeitet. Diese Bilddateien 
umfassten die Sequenzen T1 ohne Kontrast, T1 mit Gadolinium-Kontrast, T2 und 
T2 Flair. Dies ist insofern eine Neuheit, da in den anerkannten Diagnosekriterien 
meist nur die T1 mit Gadolinium-Kontrast-Sequenzen beurteilt werden. Durch 
DoctorEye war es möglich die gewonnenen Daten zu extrahieren und in Microsoft 
Excel 2007 zu transferieren, um dort weitere statistische Untersuchungen anhand 
der Histogramme, sowie die Normalisierung der Daten durchzuführen. Neben dem 
Vergleich der Verteilung der Signalintensitäten, lag das Hauptaugenmerk auf der 
Berechnung und Interpretation der jeweiligen Maximalwerte und der 
durchschnittlichen Signalintensitäten der Histogramme und deren Entwicklung im 
zeitlichen Verlauf. Dies geschah für die verschiedenen untersuchten Gewebetypen 
in jeder MRT-Modalität, zum Zeitpunkt der Diagnose und während der 
Nachbeobachtungszeit. In 9 der 33 Patienten konnte eine komplette Follow-up-
Studie rekonstruiert und analysiert werden, unter Bezugnahme auf die DICOM-
Daten-Sets zum Zeitpunkt der Diagnose, nach Operation und nach 
Radiochemotherapie. Da sich die Histogramme der verschiedenen pathologischen 
Gewebeveränderungen in allen Modalitäten unterscheiden, bietet die Messung der 
Volumina und die Segmentierung des Tumors in den verschiedenen MR 
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Sequenzen eine optimale Möglichkeit, aktives Tumor-Gewebe, Nekrose und 
Ödem objektiv voneinander unterscheiden zu können. Zum Zeitpunkt der 
Diagnose zeigte das Histogramm aller Glioblastom in T1 mit Gadolinium-Kontrast 
eine bimodale Verteilung der Signalintensitäten. Solche Übereinstimmungen in der 
graphischen Form der Histogramme waren auch in der Verlaufsbeobachtung 
einzelner Patienten gut nachvollziehbar. 
Diese Feststellungen lassen vermuten, dass Tumoren wesentlich besser durch die 
Kombination von Histogrammen verschiedener Modalitäten beurteilt werden 
können, als durch die alleinige Berechnung des Volumens. Mit der vorgestellten 
Methode können nekrotische Areale und aktiver Tumor definiert und gleichzeitig 
das Volumen zum jeweiligen Zeitpunkt berechnet werden. Durch die 
Standardisierung der durchschnittlichen Signalintensitäten anhand einer 
Relativierung mit den Signalintensitäten des entsprechenden Liquor 
cerebrospinalis, ist es gelungen einen Unterschied zwischen den 
Signalintensitäten von Tumor und Nekrose zu verschiedenen Zeitpunkten und in 
verschiedenen Modalitäten nachzuweisen. Diese Ergebnisse lassen die 
Schlussfolgerung zu, dass die Verwendung dieser Histogramme eine innovative 
Methode ist, um neue, tumorspezifische Informationen zu gewinnen, ohne 
zusätzliche Untersuchungen am Patienten durchzuführen. Diese Methode kann 
ein ergänzendes diagnostisches Werkzeug sein, verschiedene intrakranielle 
Läsion voneinander zu unterscheiden, sowie das Ansprechen eines Glioblastoms 
auf die Behandlung oder dessen Progress zu beurteilen. 
Nichtsdestotrotz ist ein standardisiertes Verfahren zur Bildakquisition vonnöten, 
um dieses Verfahren auch Zentren übergreifend anwenden zu können und die 
Ergebnisse vergleichbar zu machen. Desweiteren ist der vorgestellte 
Segmentierungsalgorithmus noch zu zeitintensiv, um im klinischen Alltag 
angewendet werden zu können. Werden diese Einschränkungen jedoch behoben 
könnte das vorgestellte Verfahren ein einfaches und effektives Werkzeug zur 
Diagnose, Verlaufsbeurteilung und Modellbildung von Tumorwachstum und 
Therapieansprechen darstellen. 
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2 Introduction 
Brain tumors comprise a group of neoplasms that either originate from brain tissue 
itself (known as primary brain tumors) or derive from extracranial neoplasms, 
which have metastasized to the brain (known as secondary brain tumors). The 
primary brain tumors may evolve from the brain parenchyma, meninges, cranial 
nerves, and other intracranial structures (the pituitary and pineal glands). 
Even if some of the tumor entities are histologically and biologically benign, the 
constitution of the brain often blurs the differentiation between biologically benign 
and malignant. Also a small and slow proliferating tumor with little or no signs of 
malignancy may cause great damage or even prove to be lethal if located in a 
region where surgery is not possible. 
2.1 Classification of Brain Tumors 
Primary brain tumors are classified by light microscopy according to their 
predominant cell type, belonging to clearly defined histopathological and clinical 
features. Since the German pathologist Rudolf Virchow first introduced the term 
“glioma” in 1860 [91] there have been many attempts of developing a classification 
system for brain tumors. More than 30 years ago, the international classification of 
diseases for oncology (ICD-O) was installed and since then serves as an 
indispensable guideline for the grading of cancers by providing histopathology and 
mortality data for epidemiological as well as oncological studies [93]. In 1979, the 
World Health Organization (WHO) published a classification system, which was 
meant to be the first edition of histological typing of central nervous system (CNS) 
tumors [170]. Since then it is continuously updated, e.g. by the introduction of 
immunhistochemistry and genetic profiling as well as clinical signs, symptoms, 
imaging and many other attributes, aiming at a refined classification [75, 76]. The 
most recent version of the WHO classification system was published in 2007 and 
has combined a nomenclature with an implied grading system, so that the actual 
histological diagnosis correlates with the histological grade of the tumor [93]. A 
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higher grade in this classification system implies a higher mitosis rate, more 
vascular proliferation, giant cells and areas of necrosis (see also chapter 2.4.2 - 
Histopathology). Strikingly, even a histologically relatively well-differentiated 
glioma (e.g. the grade II astrocytoma) can show a tendency to diffusely infiltrate 
the brain and to be biologically highly malignant due to the tumor cells capacity to 
actively migrate along structures within the neuropil. To make matters worse, 
additionally the gliomas show the inherent capacity to progress to a more 
malignant phenotype [93]. 
All these phenomena account for the low survival rates even after all therapeutic 
modalities have been utilized. 
2.2 Gliomas 
The term “glioma” refers to neoplasms believed to be derived from glial cells, e.g. 
astrocytes, oligodendrocytes and ependymal cells. Each of this cell type is capable 
of turning into a certain tumor entity, although many gliomas consist of a 
composite of them [57]. Among the gliomas themselves, which form 30-50% of all 
brain tumors, there are about 50% high malignant glioblastoma (grade IV), 25% 
astrocytomas (grade I-III), 5-18% oligodendrogliomas and 2-9% ependymomas 
[57]. The incidence of gliomas in the United States and in Europe is with 7-
11/100.000 citizens significantly higher than in Asia with 2-4/100.000 citizens. Men 
are affected more often than women [57]. 
2.3 Clinical Manifestation of Malignant Gliomas 
The malignant gliomas (WHO grade III and IV) are a group of rapidly progressive 
brain tumors that are divided into anaplastic gliomas (anaplastic astrocytoma, 
anaplastic oligodendrogliomas, and anaplastic oligoastrocytoma) and glioblastoma 
multiforme (GBM), based upon their histopathologic features [93, 157] (see also 
chapter 2.4.2 - Histopathology). 
The clinical manifestations of malignant gliomas depend upon the location as well 
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as the size of the lesion and act similar to those produced by other primary and 
metastatic brain tumors [17]. 
The Glioma Outcome Project illustrated the spectrum of symptoms produced by 
malignant gliomas by a series of 565 glioma patients (147 grade III and 418 grade 
IV) [34]: 
 Headache emerged in 53 to 57 % of cases. 
 Seizures were found in 56 % of patients with grade III lesions, compared 
with 23 percent in those with grad IV lesions. 
 Other symptoms which were seen in 20 % or more of the patients included 
memory loss, motor weakness, visual symptoms, language deficit and 
cognitive and personal changes. 
2.4 Diagnostic Procedures of Brain Tumors 
2.4.1 Diagnostic Neuroimaging 
To diagnose a patient presenting with signs and symptoms suggesting a brain 
tumor, neuroradiologic imaging is the most important diagnostic modality. MRI has 
become the method of choice in the evaluation of neurological disorders, while 
computer tomography (CT) is used in many cases only in an emergency situation 
or to clarify specific issues [151]. As of all brain tumors the malignant gliomas 
grade III and IV have the highest prevalence in older adults and are the ones with 
the poorest prognosis, it is up to the differential diagnosis to distinguish the variety 
of tumors, as well as benign lesions from these high-grade gliomas [151].  
2.4.1.1 Magnetic Resonance Imaging 
MRI is one alternative of noninvasive tumor imaging. It is characterized by high 
spatial resolution (50-500 µm) and the use of non-ionizing radiation. 
Usually a T1 with gadolinium contrast enhancement sequence (Gd-MRI) is the 
only test needed to suggest a brain tumor, while MRI may also deliver information 
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that indicates the specific tumor type: 
 Typically malignant gliomas appear hypointense on T1-weighted images, 
and enhance heterogeneously following contrast infusion. Hence, an 
enhancing tumor can be distinguished from the surrounding hypointense 
signal of edema on T1-weighted sequences[161]. 
 Without regard to the histologic grade, astrocytomas in general tend to 
show increased T2 and T2 Flair (fluid attenuated inversion recovery) signal 
intensity (SI), whereas some astrocytomas do not manifest in Gd-MRI [123]. 
Additionally to permitting visualization of the tumor mass and its relationship to the 
surrounding normal parenchyma, MRI is also superior to CT for the evaluation of 
the meninges, subarachnoid space, and posterior fossa, and for the definition of 
the vascular distribution of the abnormality [161]. 
2.4.1.2 Computed Tomography (CT) 
The CT has mostly been replaced by the cranial MRI as the imaging modality of 
choice for brain tumors. Nonetheless it remains useful in selected situations [161]: 
 Investigation of the skeleton and vascular system. 
 Search for metastases in regions around the foramen magnum, the clivus 
or the skull base. 
 In cases of emergency, where CT has a higher availability and a faster 
execution than MRI. 
 In any cases where MRI is contraindicated (e.g. implants, containing iron). 
2.4.1.3 PET-Scans 
The Positron Emission Tomography (PET) is an excellent technique for the 
visualization of metabolic and functional processes. In the oncological context it is 
used to detect malignant tumors with high metabolic rates by the help of 
radiolabeled glucose and amino acid molecules [161]. Normally tumors exhibit an 
increased metabolic activity, which can be shown by a higher radiotracer influx 
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compared to the surrounding tissues [161].  
2.4.1.4 Additional Imaging Methods 
Due to certain difficulties interpretation of MR images, which will be discussed in 
the following, and to improve the monitoring of tumors under treatment and during 
follow-up, there are certain methods, which can depict changes in the cellular 
metabolism (Magnetic resonance spectroscopy (MRS)), the perfusion (Perfusion-
MRI or -CT), as well as the cellular texture of the tumor and perifocal edemas 
(Diffusion weighted imaging (DWI)) [151]. 
Also worth mentioning are the Functional MRI, to detect eloquent areas of the 
brain in the context of surgery, and the SPECT imaging (Single photon emission 
CT), which is used to detect abnormalities of the blood-brain barrier. 
2.4.2 Histopathology 
Histological examination of a putative brain tumor remains the most important 
component of the diagnostic evaluation of brain tumors. Furthermore, the 
microscopic examination is the precondition to differentiate between the various 
subtypes of neoplasms and to grade malignancy [28]. It is important to mention 
that astrocytomas extensively infiltrate into the healthy brain tissue, and especially 
the GBM proved to display a great variety in the extent, the geometry and the 
character of the infiltrating margin [28]. 
The WHO classification of 2007 comprises 4 different grades standing for an 
“ascending malignancy scale” of intracranial neoplasms. While grade I tumors are 
characterized by a low proliferative potential and offer the chance of cure after 
resection, neoplasms ranked in grad II show infiltrative growth and tend to recur. 
Moreover, some types of grade II tumors can progress to high-grade 
malignancies, for example the low-grade diffuse astrocytoma can develop to an 
anaplastic astrocytoma or even to GBM. The tumor classification of WHO grade III 
matches to histological evidence of malignancy such as strong mitotic activity or 
nuclear atypia [93, 157].  
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Concluding, the WHO grade IV category refers to tumors characterized by 
microvascular proliferation and / or necrosis in addition to the aforementioned 
features [93, 157]. 
2.4.3 Molecular Genetics 
The formation and progression of diffuse gliomas involve an accumulation of 
genetic alterations, which mainly affect the regulation of cell proliferation, 
differentiation, and apoptosis [18]. As with many other types of human cancers the 
activation of oncogenes, inactivation of tumor suppressor genes, abrogation of 
apoptotic genes and the deregulation of DNA repair genes play a critical role in the 
pathogenesis of gliomas [18]. 
As mentioned before, GBMs can arise de novo (primary GBM), usually in older 
patients, or evolve from low-grade gliomas (secondary GBM), normally in younger 
patients. The observed molecular changes differ in these two settings [18]. 
In the different steps of the evolution of malignant gliomas multiple pathways can 
be involved, which appear to include different molecular events. For instance, 
primary GBMs are associated with a variety of molecular changes, most 
remarkably the epidermal growth factor receptor (EGFR) amplification of 
overexpression [94]. Then again, in secondary glioblastomas and lower-grade 
gliomas, typically alterations of the IDH1 and IDH2 genes [165], a 
hypermethylation genotype [106] and inactivation of the TP53 tumor suppressor 
gene can be found [92]. In the changeover from low-grade to high-grad gliomas 
the inactivation of other tumor suppressor genes on chromosomes 9p, 13q and 
19q appear to be of significance [143, 166]. 
Since the survival of patients with malignant gliomas vary substantially and cannot 
be entirely explained by differences in histologic grading or clinical parameters, 
such as age or performance status, genetic markers may be valuable both, in 
assessing prognosis and response to treatment and to predict individual courses 
of disease [63, 67]. Today, genomic analysis can identify four different and 
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clinically relevant subtypes of glioblastoma, which respond differently to treatment 
options as chemotherapy and radiotherapy, namely Proneural, Neural, Classical, 
and Mesenchymal. These four subtypes are characterized by abnormalities in the 
genes of PDGFRA, IDH1, EGFR and NF1 [147].  
2.5 Treatment and Prognosis of Malignant Gliomas 
2.5.1 Initial surgical Approach 
The initial surgical resection is the treatment of choice for malignant gliomas. 
Although maximal resection is an important goal, the extent of surgery must be 
balanced with preservation of neurologic functions [17]. 
The tumor resection has three objectives [17]: 
1. The extraction of sufficient tumor-tissue for accurate histological and 
molecular diagnostics. 
2. The potentially improvement of clinical symptoms like seizures or 
neurological deficiencies.  
3. The reduction of the tumorous cell population, in order to improve the 
overall prognosis. 
Within a substantial retrospective study, including 416 patients, Lacroix et al. 
showed in 2001 that an aggressive resection of 98% or more of the tumor volume 
was a significant, independent predictor of survival in the entire patient population 
[84]. The best currently available data, concerning an influence of the extent of 
resection on the prognosis and the advantage of complete resection compared 
with partial resection, is given in a post-hoc-analysis of data from a prospective-
randomized study about fluorescence supported resection of glioblastoma [118]. 
This study could prove a significant advantage of total resection over partial 
resection regarding the median survival, which was 16,7 versus 11,8 months [111, 
132, 133]. 
In addition to the survival benefit, the surgical resection often comes along with an 
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improvement of clinical symptoms [35]. Furthermore, an extended resection 
permits a more extensive extraction of sufficient tumorous tissue for 
histopathological diagnosis and molecular analysis, compared to stereotactic 
biopsy. 
2.5.2 Adjuvant Radiation Therapy 
Due to the high rate of recurrence in malignant gliomas, the adjuvant radiation 
therapy (RT) is indispensable, at least in malignant gliomas, as part of the 
standard-of-care therapy, using the so called involved field radiation therapy 
(IFRT), which has replaced the whole brain radiation therapy (WBRT) [27, 125]. 
Already in late 1970s the survival benefit of postoperative RT could be 
demonstrated in different studies and is still valid [11]. A daily application of 1,8-2,0 
Gy up to a cumulative dose of 60 Gy in 6 weeks is the radiation-scheme which has 
shown the best results in GBM, as well as in grade III gliomas with a median 
survival of 9-12 months and 3-5 years, respectively [77].  
MRI and functional imaging like [18F]Fluorethyltyrosin(FET)-PET or MRS 
increasingly established themselves in the planning of radiation therapy [86].  
2.5.3 Adjuvant Chemotherapy 
Because of the blood-brain barrier, the applicability of cytostatic agents in the 
treatment of malignant brain tumors is extremely limited. The most utilized 
chemotherapeutics are the lomustine (CCNU) and nitrosoureas carmustine 
(BCNU), as well as the alkylating benzamid procarbazine [9]. 
Since 2005, the combination of RT and concomitant and adjuvant chemotherapy, 
using the alkylating agent temozolomide (TMZ), represents the standard regime in 
the treatment of WHO grad IV glioma after surgery [9]. 
In contrast to other combined chemotherapy and radiation regimes, which showed 
no significant survival benefit (e.g. RT plus mitomycin [59]), the concomitant and 
adjuvant TMZ application proved to result in a survival advantage [12, 134]. This 
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statement was supported in a Cochrane review from 2008, published by Hart 
et al., conforming the therapeutic effectiveness and the low incidence of early 
adverse events caused by TMZ [62]. Recently, also Koukourakis et al. reviewed 
investigations on the mechanism of action as well as on resistance effects of 
TMZ[78]. Additionally, this review also presents current clinical studies and 
applications of temozolomide. As reported by Happold et al., patients with a 
methylated O6-methyl-guanine DNA methyltransferase (MGMT) promoter show 
clinical benefits, being more sensitive to alkylating agents such as TMZ [60]. 
2.5.4 Prognosis 
While the tumor grade is of critical prognostic value, also other criteria like the age 
of the patient, tumor location, proliferation indices, genetic alterations and many 
more are to be considered in the prediction of survival time [93]. In spite of 
substantial research for new therapeutic approaches the mean survival of a patient 
with malignant glioma could not be appreciably improved [93]. 
On average, patients who suffer from a WHO grade II glioma survive 5 to 7 years 
after diagnosis, while the ones who suffer from grade III gliomas have an average 
survival of 2-3 years. In contrast, patients with GBM (WHO grad IV) succumb to 
the disease in large part within 1 year after diagnosis [93, 116]. One of the rare 
improvements in the prognosis of GBM recently could be achieved by the 
concomitant and adjuvant application of TMZ plus RT, resulting in a prolongation 
of the survival period from 12 to 15 months [134]. So-called long-term survivors, 
who outlive the disease for more than 5 years, are very rarely seen (3-5% of 
glioma patients) [80]. Exact reasons for such a long-term survival are still unclear, 
although several clinical factors seem to be beneficial, in particular young age at 
the point of diagnosis [80]. 
2.6 Assessment of Response and Progression and its Limitations 
Despite aggressive therapy, in most cases glioblastoma eventually develop a 
progressive or recurrent course of disease. 
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The individual decision making for each patient requires an assessment of both, 
response to treatment, as well as following diagnosis of a progressive disease.  
Since 1990 the MacDonald-Criteria, which rely upon measurement of areas of 
contrast enhancement, have been the standard approach for patients with 
malignant glial tumors (Table I) [95]. Even if proved to be helpful these criteria are 
subject to a number of significant limitations, mainly due to innovative biologically 
active systemic therapy, as well as to substantial improvement in MRI technology 
[23]. The Response Assessment in Neuro-Oncology (RANO) Working Group, 
which is an international, multidisciplinary group, pointed out these limitations in 
2010 and also proposed new approaches to evaluate the behavior of malignant 
gliomas [156, 158]. 
2.6.1 MacDonald Criteria 
2.6.1.1 Response Criteria 
The MacDonald Criteria for response assessment in high-malignant gliomas were 
primarily based on contrast-enhanced CT and the two-dimensional WHO oncology 
response criteria using enhancing tumor area (the product of the maximal cross-
sectional enhancing diameters) as the primary tumor measure [101]. In 2000 the 
Response Evaluation Criteria in Solid Tumors (RECIST) first introduced the use of 
one-dimensional measurements [138] and were recently revised (RECIST version 
1.1 – [47]). Subsequently, different studies have compared the RECIST criteria 
with two-dimensional measurements, three dimensional measurements and 
volumetric measurements in malignant gliomas [53, 124, 152]. These studies 
show that there is a good conformance among the different methods in 
determining response in adult patients with both, newly diagnosed and recurrent 
high-grade gliomas [53, 124], as well as in pediatric brain tumors [152]. Still there 
have been no studies prospectively validating the RECIST criteria in gliomas. 
Therefore MacDonald Criteria are still widely used as a reference for assessing 
tumor response in clinical trials, but also for the reason that they enable the results 
of ongoing studies to be easily compared with historical data. 
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The MacDonald Criteria define the following four possible outcomes: 
Table I. Current Response Criteria for Malignant Gliomas 
(Macdonald Criteria [95]) 
Response description Response criteria 
Complete response (CR) Requires the following:  
Disappearance of all enhancing measurable and 
nonmeasurable tumor on consecutive CT or MRI scans 
sustained for at least 1 month, no new lesions, no 
corticosteroids, and neurologically stable or improved  
Partial response (PR) Requires all of the following: 
 ≥ 50% reduction in cross-sectional area of all measurable 
enhancing lesions on consecutive CT or MRI scans 
sustained for at least 1 month, no new lesions, 
corticosteroid stable or reduced, and neurologically stable 
or improved 
Progressive disease (PD) Defined by any of the following:  
 ≥ 25% increase in cross-sectional area of enhancing 
lesions or any new lesion on CT or MRI scans, or 
neurologically worsening and steroids stable or increased 
Stable disease (SD) Requires all of the following:  
All other scenarios 
 
2.6.1.2 Limitations of the MacDonald Criteria 
Besides making new approaches in the evaluation of tumor response and 
progression the RANO Working Group pointed out the following limitations of 
MacDonald Criteria [158]: 
 Pseudoprogression: Pseudoprogression is defined by increased contrast 
enhancement at the first reimaging after RT, which then resolves under 
continued therapy. Approximately one-fourth of patients with glioblastoma 
have evidence of pseudoprogression after receiving the standard treatment 
for malignant gliomas which consists of initial surgery followed by radiation 
therapy and concurrent and adjuvant chemotherapy (see 5.2.2 Imaging 
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Phenomena: Pseudoprogression, Radiation Necrosis and 
Pseudoresponse). 
 Surgical changes: Like Cairncross et al. already showed in 1985, a 
postoperative contrast enhancement in the wall of the surgical cavity in the 
first 48 to 72 hours is significantly common [29]. While neuroradiology is 
aiming to find a way to distinguish these areas from residual tumor, that 
failed to be resected, this confusion can easily be avoided by a baseline 
MRI obtained within 24 to 48 hours after surgery. 
 Pseudoresponse under antiangiogenetic treatment: Recent approaches in 
glioblastoma therapy target the Vascular Endothelia Growth Factor (VEGF) 
pathway, which plays a critical role in the tumor genesis. First results 
showed an immediate decrease of contrast enhancement. Since the effect 
on overall survival is limited the conclusion of a tumor regression is 
doubtful. This effect, known as pseudoregression or pseudoresponse, 
proves another limitation of the MacDonald Criteria, namely that they do not 
take non-enhancing tumors into account (see 5.2.2 Imaging Phenomena: 
Pseudoprogression, Radiation Necrosis and Pseudoresponse). 
 Other issues: Furthermore, irregularly shaped tumors, multiple tumors and 
enhancing lesions in cyst walls following surgery are not considered 
adequately.  
Like Warmuth-Metz recently pointed out, the MacDonald Criteria also suffer from 
measuring inaccuracy, since they only rely on contrast enhancing tissue [151]. The 
enhancement of contrast can easily be influenced by changes in the amount of 
contrast applied, the contrast’s kinetics or the MRI-sequence’s sensitivity for the 
contrast agent. Also technical parameters like changes in sequences and the 
magnet-field’s size can worsen that inaccuracy. 
2.6.2 The RANO Criteria 
The main complementing features contemplated by the RANO Working Group 
include the following criteria for progressive disease [158]: 
Introduction 
18 
 Contrast enhancement outside the radiation therapy field or histologic 
evidence of viable tumor on biopsy sample during the first twelve weeks. 
The histologic analysis serves to distinguish pseudoprogression from real 
progression. Assuming progression only by clinical signs is not adequate 
during this initial period. 
 New contrast enhancement outside the radiation field or an increase in size 
of the original lesion after the first 12 weeks. For patients taking an 
antianiogenetic drug such as bevacizumab the increase of nonenhancing 
lesion, as visualized in T2/T2 Flair image sequences, should be taken into 
consideration. 
Concerning complete response, partial response, and stable disease the 
definitions of RANO Criteria confirm those from MacDonald. 
Even if the RANO criteria take innovative treatment options and recent alterations 
in neuroimaging into account, they still lack in accuracy [24]: 
 It is the first time that changes in T2-weighted sequences are taken into 
consideration, but there is no specific quantitative measurement given to 
evaluate these changes. This might be due to MR-parameters, as well as 
measurement technology, but to define progress as a “significant increase” 
of the lesion in T2/T2 Flair leaves much room for interpretation. However, 
up to date there are no reliable technologies existing to perform volumetric 
measurements.  
2.6.3 Conclusion 
As seen, despite extensive opportunities to make a relatively accurate diagnosis 
and even if the criteria for assessing response to treatment and progressive 
disease recently have been revised, this process obviously has much potential for 
improvements. To avoid that efficacious therapy will be discontinued prematurely, 
or that an ineffective treatment will be continued without benefit, it is very important 
to have an accurate and standardized way of assessing the response and 
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progress in patients suffering from GBM. From the clinical perspective, a major 
issue is how to differentiate between pseudo-early progression and real early 
progression immediately after RT.  
 
2.7 Objectives 
The aim of our study is to establish a new method of gaining tumor-specific 
information by analyzing MRI scans using DoctorEye - an open-source software 
tool. Our analysis will not only include the segmentation and volumetric 
measurement of tumor-suspicious and enhancing areas, as performed already, 
but also evaluate the distribution of signal intensities in forms of histograms. 
Additionally we will try to subdivide the pathologic findings into active tumor, 
necrosis and edema, to achieve more accurate results and to evaluate their 
development separately and in comparison. 
Primary we want to find out, if our method reveals an average pattern of SI-
distribution in newly diagnosed GBM. If so, we will proceed to review the patients 
follow up and to evaluate the SI changes during treatment, all with the goal of 
finding typical similarities, which can describe the tumors characteristics and might 
help to predict its development. 
Additionally to the aim to generally improve the assessment of response to 
treatment and progressive disease, our study will consequently lead to the 
approach of differentiating real progression from pseudoprogression and radiation 
necrosis, real response from pseudoresponse and postoperative contrast 
enhancement from residual tumor. In addition our method might facilitate the 
essential differential-diagnosis of GBM to other intracranial lesions and the 
detection and measurement of multiple contrast-enhancing and irregular-shaped 
lesions. 
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3 Materials and Methods 
This research was done within the ContraCancrum- (Clinically Oriented 
Translational Cancer Multilevel Modelling; project reference number: 223979; 
http://contracancrum.eu/ ) and TUMOR-project(Transatlantic Tumour Model 
Repositories: project reference number: 247754; http://tumor-project.eu/ ), which 
were funded under the 7th Framework Program of the European Commission.  
Both projects and the related researches are approved by the Ethical Committee 
of the ‘Ärztekammer des Saarlandes’ at the 20th of July 2010 (code number: 
104/10; Appendix 9.4 Ethical Approval, Figure 38).  
3.1 Image Acquisition 
33 patients with assured or suspected glioblastoma were included into the study 
group. To maintain absolute confidentiality all 33 patients were anonymized as G0, 
G1, G2, (…), up to G32. Except one, all of them were diagnosed within the years 
2004 and 2008. The intracranial lesion from 4 of the 33 study subjects 
histologically turned out not to be a WHO Grade 4 glioma, whereas the intracranial 
lesion from 1 of the 33 study subjects could not be securely diagnosed (Table II). 
The corresponding MRI-files were provided by Prof. Reith, Head of the 
Department of Neuroradiology, at the University of Saarland, Homburg, Germany. 
In total this collection contained more than 22.000 single DICOM-images (Figure 
1), including T1, T1 Gd-MRI and T2 sequences, which entirely have been 
examined and rendered. 
Commonly used inclusion criteria as gender and age did not play a crucial role, 
since the statistical analysis of the pathologic MRI-scans was the study’s key 
aspect (Figure 2).  
Finally, only scans created at the time of diagnosis, after surgery (if performed) 
and after RT and chemotherapy were taken into account, to provide a 
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standardized overview of the patient’s individual course of disease and an easy 
comparability between the study subjects. 
Due to the individuality of the different cases and the aggressiveness of the 
disease, a complete follow up (MRI-scans at diagnosis, after surgery, after radio- 
and chemotherapy) was available in 9 of the 33 cases. 
 
Figure 1: DICOM Data-Set 
DICOM data-set of whole study group (33 patients), with 22.014 files and a total size of 6,71 
Gigabytes. 
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Table II. Study Group – Date of Diagnosis, Histology and WHO grading 
 
PseudonymDate of diagnosis Histology WHO grading 
G-0 11.11.2005 Astrocytoma 2
G-1 22.01.2008 Anaplastic Carcinoma  -
G-2 15.02.2008 Glioblastoma 4
G-3 12.09.2007 Glioblastoma 4
G-4 09.01.2008 Glioblastoma 4
G-5 29.06.2007 Glioblastoma 4
G-6 27.10.2006 Glioblastoma 4
G-7 11.02.2008 Glioblastoma 4
G-8 15.02.2008 Bronchial Cancer  -
G-9 18.02.2008 Glioblastoma 4
G-10 19.02.2008 Glioblastoma 4
G-11 25.02.2008 Glioblastoma 4
G-12 26.02.2008 Glioblastoma 4
G-13 05.03.2008 Glioblastoma 4
G-14 08.04.2008 Glioblastoma 4
G-15 14.04.2008 Astrocytoma 3
G-16 22.04.2008 Glioblastoma 4
G-17 15.05.2008 Glioblastoma 4
G-18 20.06.2008 Glioblastoma 4
G-19 23.07.2008 Glioblastoma 4
G-20 30.07.2008 Glioblastoma 4
G-21 04.08.2008 Glioblastoma 4
G-22 19.08.2008 Glioblastoma 4
G-23 26.03.2008 Glioblastoma 4
G-24 04.09.2008 Glioblastoma 4
G-25 19.09.2008 Glioblastoma 4
G-26 26.11.1998 Glioblastoma 4
G-27 24.08.2004 Glioblastoma 4
G-28 22.03.2006  -  -
G-29 02.05.2006 Glioblastoma 4
G-30 05.05.2006 Glioblastoma 4
G-31 25.04.2005 Glioblastoma 4
G-32 09.03.2006 Glioblastoma 4
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Figure 2: Age Distribution of the Study Group 
 
3.2 Investigation Process and Equipment Technology 
3.2.1 Principles of the MRI 
The magnetic resonance imaging is a medical imaging technique, which is based 
on the physical principles of the nuclear magnetic resonance (NMR). Bloch and 
Purcell in 1946 coincidently developed a method to detect this nuclear resonance 
[13]. In 2003 Paul Lauterbur and Sir Peter Mansfield even were awarded with the 
Nobel Prize in Physiology or Medicine for their discoveries concerning the field of 
MRI [13]. 
An MRI scanner is a device that is able to generate a strong static magnetic field. 
Atomic nuclei have an intrinsic angular momentum (nuclear spin), which describes 
the direction and strength of a magnetic field surrounding the nucleus and is 
substance-specific [38]. The most important element for NMR investigations is the 
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nucleus of hydrogen, the proton, which is the most basic and the most frequent 
atomic nucleus in the human body [13].  
While the patient lies within the scanner, the imaging magnet produces a strong, 
constant external magnetic field. Under the influence of this magnetic field a 
fractional part of the nuclei get directed into the direction of the static field, thus 
generating a macroscopic, measurable magnetic moment [38]. The induced 
motion of the spin around the magnetic field is called precession and is 
proportional to the strength of the applied field. The rate at which the spin 
precesses is known as the Larmor frequency [13].  
3.2.2 Image Generation 
To generate an image, the protons have to be excited. This excitation is achieved 
by the application of an additional, momentary, high-frequency alternating field. 
Immediately after their excitation, the nuclei return to their ground state, a 
measurable process that is called relaxation, which differs depending on the 
chemical compound, and the molecular environment of the hydrogen atoms, 
whereby different signal intensities are generated in the resulting image [117]. 
The relaxation is composed of two different processes, the longitudinal and 
transversal relaxations, which are described through tissue-specific time 
constants, T1 for the longitudinal relaxation, lasting 300 – 2000 msec, and T2 for 
the transversal relaxation, lasting 30 – 150 msec. Since the impulse that is emitted 
during the longitudinal relaxation is very little, protons are excited repeatedly by a 
so called pulse-sequence. The repetition time (TR) is the amount of time between 
two single pulses, whereas the elapsed time from the pulse to the peak of the 
echo is called the echo time (TE) [117]. 
Different body tissues generate different signal intensities in MR images, 
depending on the specific tissue properties (T1, T1, and proton density), sequence 
parameters (TR and TE) and the type of sequence. Thus, a contrast between 
different tissues can be generated [117].  
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3.2.3 MRI Sequences 
The MRI includes a broad range of imaging sequences, however, our 
investigations are limited to only a part of these. In our study we examined the two 
classical sequences T1 and T2, as well as their variations, T1 Gd-MRI and T2 
Flair. Other sequences that are comprised within the spectrum of MRI, although 
not part of our study, include susceptibility-weighted imaging (SWI), diffusion- and 
perfusion-weighted imaging (DWI and PWI), and MR angiography. 
The T1-and T2-weighted images are the classical sequences for the anatomical 
representation of the brain and the CSF. The T1-weighted imaging refers to the 
longitudinal relaxation and describes the process of the regeneration of the 
longitudinal magnetization, dissipating measurable energy (spin-lattice relaxation). 
It is characterized by a short TE and TR. Typically tissues that have a short T1 
time constant and contain lipids are displayed hyperintense (e.g. white matter and 
fat), whereas tissues with a long T1 time constant appear hypointense (e.g. gray 
matter, muscle and CSF) [13, 117]. The T2-relaxation time, referring to the 
transversal relaxation, is determined by the rate of the reduction of the transverse 
magnetization, a process that does not emit energy, and can draw conclusions 
about the interaction of the spins between various nuclei (spin-spin relaxation). 
The T2-sequence has typically longer TE and TR and displays tissues with a long 
T2 time constant hyperintense (e.g. water), whereas tissues with a short T2 time 
constant appear hypointense on T2-weighted images (e.g. muscle) [13, 117].  
Usually, a clinical MRI examination includes T1-and T2-weighted image series in 
at least two spatial planes. In the gadolinium contrast-based T1-weighted 
sequence paramagnetic contrast agents (chelates of gadolinium) are used and 
administered intravenously. On such a T1-weighted image the accumulation of the 
contrast-agent is represented by increased SI, and is usually equivalent to an 
increased vascularity [38]. In the T2 Flair sequence the very high signals from the 
CSF in T2-weighted images are suppressed, which is of particular benefit if one 
wants to define a lesion that adjoins to the CSF [13]. 
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By the variation of pulse sequences the MRI is able to emphasize on differences in 
T1, T2 or proton density. Based on the choice of the imaging sequence it is 
possible to detect small differences in the microenvironment of different tissues, 
being flexible in determining the tissue contrast [38]. 
3.2.4 MRI Scanner 
In all patients cranial MR images were acquired by the use of a 1.5 Tesla whole-
body MRI scanner produced by Siemens (Siemens 1.5T MAGNETOM Vision; 
Figure 3). 
 
Figure 3: Siemens 1.5T MAGNETOM Vision MRI Scanner [8] 
3.3 Image-Analysis 
All the images have been preprocessed and analyzed at the Department of 
Pediatric Oncology and Hematology from the University of the Saarland between 
the years 2010 and 2012. The image-rendering was performed with the DoctorEye 
software, a multifunctional open platform for fast annotation and visualization of 
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tumors in medical images [128], while the statistical analysis was done using 
Microsoft Office Excel 2007. 
3.3.1 Background on DoctorEye (4.7) 
DoctorEye is a flexible and easy-to-use annotation platform with a Graphical User 
Interface (GUI) for quick and precise identification and delineation of tumors in 
medical images, under the GNU General Public License [128]. Being an open-
source software tool, DoctorEye easily can be downloaded and tested 
(http://biomodeling.ics.forth.gr; Figure 4). As a clinically driven, interactive and 
multifunctional platform, DoctorEye is frequently revised, to ensure that it can be 
efficiently and intuitively used to annotate large numbers of tomographic datasets 
in the clinical setting. Our close collaboration during the research with the 
developers from the biomodeling group of the BioMedical Informatics [BMI] 
laboratory of FORTH1 in designing the platform helped to optimize the software’s 
user-friendliness and its practical applicability.  
                                            
1 Foundation for Research and Technology – Hellas, Crete, Greece; 
http://www.forth.gr/ 
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Figure 4: DoctorEye Webpage  
Publicly accessible webpage of the biomodeling group, which is part of the BioMedical Informations 
[BMI] laboratory, of FORTH, offering free download of the DoctorEye software and associated files 
- http://biomodeling.ics.forth.gr. 
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3.3.2 Selected Segmentation Method – The Magic Wand Algorithm 
The “Magic Wand” Algorithm is a segmentation tool for semiautomatic rendering, 
which provides high accuracy. Its function is based on finding and selecting all the 
pixels neighboring a predefined, user-selected initial point that are sufficiently 
similar in gray level. To determine how broad the range of summarized gray levels 
is, a tolerance value can also be set by the user (higher tolerance ends up in 
larger selection). If the desired preciseness cannot be achieved by only using the 
magic wand, DoctorEye offers two additional tools for manual refinement, the 
“Pencil” and the “Eraser” (Figure 5). 
 
Figure 5: DoctorEye Task Bar with the Annotation-Tools "Pencil, Eraser" and the "Magic 
Wand" 
3.3.3 Preprocessing 
Segmentations were performed of sequences T1, T1 Gd-MRI, T2 and T2 Flair. To 
specify our results suspected active tumor tissue, necrosis, edema and the 
cerebrospinal fluid (CSF) were separately analyzed in all mentioned sequences. 
To ensure the highest accuracy, all the segmentations were performed by 
semiautomatic rendering of the areas of interest using the so-called “Magic Wand 
Algorithm”. Figure 6 shows an exemplary graphical user interface of the 
DoctorEye 4.7 software, while Figure 7 illustrates the comparison between the 
raw and the processed version of an MR-Image. Additionally, DoctorEye offers the 
option to create a three-dimensional visualization of the segmented tumor 
including all annotations.  
Signal intensities of the CSF were used as reference values for standardization of 
signal intensities within the tumor. After rendering tumor volumes were calculated. 
To guarantee the highest grade of correctness supervision was performed by Prof. 
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Dr. Reith, an expert in the field of neuroradiology and Head of the Department of 
Neuroradiology at the University of Saarland, Homburg, Germany.  
 
 
Figure 6: Graphical User Interface (GUI) of DoctorEye 4.7. 
This snapshot of the software’s main window shows an example of a glioblastoma at the time of 
diagnosis. The contrast enhanced tumor is shown in red, cystic/necrotic area in dark blue/purple 
and edematous area in light blue. Cerebrospinal fluid is marked in yellow (only part of the left and 
right side ventricle). 
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Figure 7: Comparison between raw and processed MR-Image 
For illustrative purpose, the comparison between a raw (left side) and a processed MR-Image (right 
side) from Patient G-13 at diagnosis is shown (sequence = T1 with gadolinium contrast). The 
contrast enhanced tumor is shown in red, the cystic/necrotic area in dark blue/purple and the 
edematous area in light blue. Cerebrospinal fluid is marked in yellow (only parts of the left and right 
side ventricle). 
 
3.3.4 Measurements and Analysis 
DoctorEye provides the calculation of histograms of the rendered areas and the 
corresponding mean and median values (Figure 8). Histograms were created in 
every patient, based on the four different areas of interest (active tumor, necrosis, 
edema and CSF), in all four investigated MRI-sequences (T1 without contrast, T1 
Gd-MRI, T2 and T2 Flair). The histograms’ data were uploaded to Microsoft Office 
Excel 2007, to perform further statistics, including the normalization of the data 
(Figure 9; 3.3.5 Statistical Analysis). A comparisons of the histograms’ graphical 
shape and the signal intensities’ mean and median value of different tumor areas 
were performed for each sequence, at the time of diagnosis and during follow-up, 
in individual patients and inter-individually. In 9 of the 33 patients a complete 
follow-up could be analyzed, referring to DICOM data-sets at diagnosis, after 
surgery and after radio- and chemotherapy. Up to now, a quantitative analysis of 
signal intensities is not possible, due to the variety of MR machines and the lack of 
standardization in producing MR-images.  
Materials and Methods 
32 
 
Figure 8: Histogram calculated by DoctorEye 
This diagram shows the graphical representation of a signal-intensity histogram, automatically 
provided by the DoctorEye software. The histogram corresponds to the rendered MR-Image in 
Figure 6 and Figure 7. 
 
 
 
 
Figure 9: Histogram Data Transfer into Microsoft Office Excel 2007 
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3.3.5 Statistical Analysis 
The definition of possible outcomes in our study for the evaluation of our results 
from active tumor, necrosis and edema and their volume-development was based 
on the RECIST criteria, which were published in 2000 [138]. The definition of 
response requires a decrease of tumor size of more than 50 %, whereas 
progressive disease equals an increase of more than 25 %. Stable disease is a 
status in which neither the criteria for response nor for progressive disease are 
complied. The two exceptionally conditions pseudoprogression and 
pseudoresponse have been described inter alia in the RANO criteria from 2010 
[158]. Since in our patient collective no antiangiogenetic drugs were administered, 
we termed the status in which the development of the whole lesion indicates 
response to treatment, while at the same time the remaining results are 
contradictory, “questionable response” instead of pseudoresponse. 
The statistical analysis of the histograms, provided by DoctorEye, based on our 
segmentations, followed the subsequent steps and was performed in every single 
histogram created: 
1. Transfers of the data into a Microsoft Office Excel 2007 spreadsheet, 
creating for each MRI sequence four excel columns corresponding to the 
different segmentations, namely “active tumor, necrosis, edema” and 
“CSF”. 
2. Summarization of the histograms of “active tumor, necrosis” and “edema” to 
an additional excel histogram called “whole lesion”. 
3. Calculation of the total pixel count for each histogram. 
4. Calculation of the annotation’s volume for each histogram by multiplying the 
total pixel count by the volume of a single pixel corresponding to the 
specific image set. 
5. Calculation of SI-peak for each histogram. 
6. Calculation of mean SI: 
Sum of all SI-values multiplied with corresponding pixel-count, divided by 
sum of all pixels in that specific histogram. 
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7.  Standardization of mean SI: 
Mean SI of the three different tumor-qualities (active tumor, necrosis, and 
edema) divided by mean SI of the CSF. 
Thereafter the histograms of the whole study group were summarized by 
calculating an average histogram for each of the four areas of interest (active 
tumor, necrosis, edema and CSF), in all MRI-sequences investigated. The 
resulting mean histograms underwent the same steps mentioned before in 1.-7., 
calculating an average- total pixel count, tumor-volume, SI-peak, mean SI and 
standardized mean SI. An exemplary screenshot of such a calculation 
spreadsheet is given in Figure 10. 
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Figure 10: Histogram Analysis in Microsoft Office Word 2007 
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4 Results 
4.1 Evaluation of DoctorEye 
DoctorEye presented as an user-friendly segmentation software which allowed us 
to perform fast annotations of different data sets at the same time, with a high level 
of accuracy.  
During the two year research we stood in a lively exchange with the developers of 
FORTH. Our suggestions for improvement had a great influence on the software 
updates, particularly in optimizing the practical handling and its applicability in the 
clinical daily routine. 
4.1.1 Processing Time 
DoctorEye protrudes with its fast reaction and short processing time, which 
permits a smooth and steady workflow. For the following mentioned procedure, we 
used a laptop with “Windows 7 Professional”, an Intel® Core™2 Duo processor at 
2,20 GHz, and 4 GB of memory (RAM). The time that is required for an 
unpracticed user to completely process a directory of DICOM files, using mainly 
the “Magic Wand” algorithm, and to export the acquired histograms is listed below: 
 For getting the program started and ready-to-use: less than 15 seconds. 
 For uploading and opening one set of Images, for example T1 Gd-MRI, 
containing 19 slices of already annotated images and a file size of 10,2 MB 
(Patient = G-13; at diagnosis): less than 10 seconds. 
 For the investigation, differentiation between active tumor, necrosis, edema 
and CSF and their semiautomatic rendering in the given example (G-13 at 
diagnosis), whose lesion is rather voluminous and extends over 9 of the 19 
slices: 16:54 minutes. 
 For the processing of series of average complexity, in comparable size to 
the above mentioned: approximately 15 minutes. 
 For assembling the corresponding histograms: 3 seconds 
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 For saving the processed images, respectively the completed annotations: 
2-3 seconds. 
 For exporting the histogram-data in Excel file format: 30 seconds.  
Naturally an experienced person could distinguish and annotate the lesions in a 
much faster way. The same applies if the semiautomatic segmentation method is 
replaced by a less time-consuming automatic or semi-automatic method. 
To facilitate the usage of the software, all important features have their own 
keyboard short-cut. 
4.1.2 Accuracy 
If very high accuracy is required the semiautomatic segmentation method “magic 
wand” is the method of choice, even if it goes at the expense of the processing 
time. 
Beside technical properties, the user’s knowledge in distinguishing between 
different cerebral tissues is of great importance in that specific context. In our case 
training, control and confirmation was performed by Prof. Reith, Head of the 
Department of Neuroradiology, at the University of Saarland, Homburg, Germany. 
Even though the supervision kept on regularly during the whole research period 
the results already have been promising after a few hours of practice. 
As Figure 11 and 12 impressively illustrate, DoctorEye enables the user to 
perform most precise delineation between different areas of interest. The 
combination of the tools “Magic Wand, Pencil and Eraser” makes it possible to 
correct small details while still being effective in terms of time management. In 
every session the user is able to set a personal balance between accuracy and 
processing time, depending on current priorities in the clinical setting. If certain 
areas are difficult to demarcate, due to their structural complexity, it is possible to 
change from the “Stretch” mode, which makes the current image fill as much of the 
screen as possible, to the “Zoom In” mode. By using this feature, it is possible to 
magnify the selected area of the image to different degrees and thereby to 
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facilitate the differentiation and segmentation of the investigated structures. 
Holding the shift-key allows the user to include areas to the currently selected 
annotation, which are not in direct contact to the initial point or included in the 
preset tolerance value. This is very helpful when one wants to partially enlarge the 
marked area without increasing the tolerance level. Furthermore, the “Undo-
Function” can be used if the last added annotation not conforms to what was the 
desired area, while it is not wished to delete all previously selected parts of this 
annotation. This makes it possible to retry the selection with an unlimited number 
of attempts, until the result is satisfying. 
 
Figure 11: Illustration of DoctorEye’s high Potential of precise Delineation 
Left side: raw images, right side: processed images. 
Upper row: image overview, lower row: amplified image 
For easier delineation and to achieve more precise segmentations of the areas of interest 
DoctorEye allows the user to “zoom in” on the image using the “Magic Wand” algorithm for 
segmentation and the “Pencil and Eraser” tool for manual refinement. 
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Figure 12: Illustration of the Software’s high grade Accuracy in an amplified Image 
 
4.1.3 3D-Visualization 
Additionally to segmentation- and histogram-preparation, DoctorEye offers the 
option to create a three-dimensional visualization of the segmented tumor and all 
other findings. Figure 13 demonstrates this feature, which is given in an 
interactive window that provides the user with a choice of different environment 
settings and the possibility to change parameters concerning the viewing angle, 
the color of the annotations and many more, for the best spatial representation of 
the annotations. 
The illustrated example is the result of the segmentation of 19 cranial MR images 
(T1 with gadolinium contrast enhancement sequence), belonging to the dataset of 
patient G-13 at the time of diagnosis. 
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Figure 13: 3D-Vizualization created by DoctorEye 
Upper image: Annotated areas surrounded by all of the 19 MRI slides. 
Middle image: Annotated areas with active tumor shown in red, necrosis shown in dark blue, 
edema shown in light blue and cerebrospinal fluid shown in yellow. 
Lower image: Isolated active tumor shown in red. 
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4.2 Evaluation of the Histograms 
It is well known that different MR sequences show different shapes of a GBM in a 
single patient at the same time, as depicted in Figure 14, which makes correct 
segmentations of tumors nearly impossible. It can be shown that by measuring 
volumes and segmenting the tumor in different sequences, active tumor-tissue, 
necrotic areas and edema could be distinguished the best by using the histograms 
of the signal intensities. These are different within the tumor and vary distinctly in 
all sequences. Using combinations of histograms from different sequences the 
tumor can be described in a much better way than by calculating solely the tumor 
volume.  
 
Figure 14: Different Sequences of MR Images in a single Patient with Glioblastoma at the 
Time of Diagnosis 
This image is taken from patient G-13 at the time of diagnosis and depicts how the pictorial 
representation of intracranial lesions may differ depending on the MR sequence examined. 
 
4.2.1 At Diagnosis 
In Figure 15 the rendered images of an exemplary patient (G-13), created at the 
time of diagnosis, are given along with the corresponding histograms. It already 
emphasizes that the areas of the different tumorous tissues vary strongly in their 
SI distribution. The same applies for Table III, which demonstrates the 
mathematical analysis of the segmentation-based histograms. In Figure 16 and 
Table IV the mean histograms calculated from all patients of the study group 
(except the 4 non-glioblastomas) and their mathematical analysis are depicted. 
Also in this summary it is obvious that the SI-distribution of the different qualities 
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from the tumorous lesion act different, depending on the MR-sequence 
investigated. Also the SI-peak, the mean SI and the standardized SI of the Active-
Tumor-histogram vary strongly from the necrotic and edematous parts (Table IV) 
at the time of diagnosis. 
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Figure 15: Exemplary annotated DICOM Files of all Sequences from Patient G-13 at the Time 
of Diagnosis with corresponding Histograms of the whole Set. 
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Table III: Exemplary Excel spreadsheet demonstrating the mathematical 
Analysis of Signalintensity Histograms 
This spreadsheet exemplary shows the mathematical analysis of the histograms acquired from the 
annotations rendered in the MRI set of Patient G-13 at the time of diagnosis, presenting the results 
of the T1 with gadolinium contrast enhancement sequence.  
 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,84 4,84 4,84 4,84 4,84
Total Pixel-Count 0 0 57620 57620 11549
Total Volume (mm³) 0 0 279.062 279.062 55.933
Maximum Pixel-Count 0 0 5009 5009 413
Signalintensity-Peak  -  - 85 85 46
Mean Signalintesity  -  - 85,2 85,2 62,7
Standardization to CSF  -  - 1,36 1,36 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,84 4,84 4,84 4,84 4,84
Total Pixel-Count 16310 15956 22553 54819 7517
Total Volume (mm³) 78.992 77.277 109.227 265.496 36.406
Maximum Pixel-Count 420 1299 1531 2830 500
Signalintensity-Peak 93 63 63 63 42
Mean Signalintesity 102,6 63,8 65,4 76,0 49,3
Standardization to CSF 2,08 1,29 1,33 1,54 1,00
Tumor Necrosis Edema whole lesion CSF
Volume of 1 Pixel (mm³) 4,84 4,84 4,84 4,84 4,84
Total Pixel-Count 27286 0 52724 80010 15301
Total Volume (mm³) 131.986 0 255.032 387.018 74.013
Maximum Pixel-Count 470 0 1176 1416 265
Signalintensity-Peak 185  - 152 156 188
Mean Signalintesity 191,2  - 148,2 162,9 164,2
Standardization to CSF 1,16  - 0,90 0,99 1,00
Tumor Necrosis Edema whole lesion CSF
Volume of 1 Pixel (mm³) 4,44 4,44 4,44 4,44 4,44
Total Pixel-Count 13637 0 72557 86194 15864
Total Volume (mm³) 60.585 0 322.346 382.931 70.478
Maximum Pixel-Count 691 0 2114 2330 416
Signalintensity-Peak 142  - 133 140 12
Mean Signalintesity 155,1  - 139,1 141,7 37,9
Standardization to CSF 4,09  - 3,67 3,74 1,00
T2 
Flair
T1   
+  
Gd
T2
T1
Results 
45 
 
Figure 16: Mean Histogram calculated from all Patients at the Time of Diagnosis 
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Table IV: Results from mathematical Analysis of the mean Histograms at the 
Time of Diagnosis 
 
 
 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,29 4,29 4,29 4,29 4,29
Total Pixel-Count 1696 4221 35651 41567 12701
Total Volume (mm³) 7.273 18.107 152.926 178.306 54.482
Maximum Pixel-Count 174 198 1263 1385 600
Signalintensity-Peak 85 33 79 79 53
Mean Signalintesity 82,0 51,7 72,5 70,8 52,1
Standardization to CSF 1,57 0,99 1,39 1,36 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 2,54 2,54 2,54 2,54 2,54
Total Pixel-Count 13260 9742 31697 54700 12042
Total Volume (mm³) 33.617 24.699 80.358 138.674 30.529
Maximum Pixel-Count 221 486 1372 1837 630
Signalintensity-Peak 88 68 69 69 42
Mean Signalintesity 116,2 67,6 68,6 80,0 51,4
Standardization to CSF 2,26 1,32 1,34 1,56 1,00
Tumor Necrosis Edema whole lesion CSF
Volume of 1 Pixel (mm³) 4,12 4,12 4,12 4,12 4,12
Total Pixel-Count 9863 1393 25917 37173 15363
Total Volume (mm³) 40.623 5.737 106.744 153.104 63.277
Maximum Pixel-Count 150 62 418 504 815
Signalintensity-Peak 255 102 153 153 255
Mean Signalintesity 163,1 102,0 148,8 150,9 174,5
Standardization to CSF 0,93 0,58 0,85 0,86 1,00
Tumor Necrosis Edema whole lesion CSF
Volume of 1 Pixel (mm³) 4,43 4,43 4,43 4,43 4,43
Total Pixel-Count 8783 1561 45886 56230 16388
Total Volume (mm³) 38.878 6.909 203.104 248.891 72.537
Maximum Pixel-Count 256 45 923 1148 438
Signalintensity-Peak 144 126 140 140 17
Mean Signalintesity 141,2 104,6 142,6 141,3 34,4
Standardization to CSF 4,10 3,04 4,14 4,10 1,00
T1
T1   
+  
Gd
T2
T2 
Flair
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4.2.2 Follow-up 
In the first part of this section (4.2.2.1 Single Patient) the follow-up of an exemplary 
patient in all four investigated MR sequences is illustrated. Besides different 
exemplary MR-Images, the corresponding histograms of the whole set from each 
time point (at diagnosis, after surgery and after radiation- and chemotherapy) are 
depicted in Figure 17, showing the results from T1-, Figure 18 from T1 Gd-MRI-, 
Figure 19 from T2- and Figure 20 from T2 Flair-sequence. According to each 
sequence and histogram the mathematical analysis is presented in Tables V-VIII. 
The second part (4.2.2.2 Summary) follows the same structure as the first, only, 
instead of presenting a single patient’s results, it depicts the mean histograms 
calculated from all patients of the study group (except the 4 non-glioblastomas) 
and the corresponding mathematical analysis, shown in Figures 21-24 and 
Tables IX-XII. 
In comparison to the first and second part, the third one (4.2.2.3 Non-
Glioblastoma) pictures the follow-up of an intracranial tumorous lesion that was 
proved not to be a glioblastoma (patient G-8; brain metastasis deriving from 
bronchial cancer). To provide a clear structure only T1 Gd-MRI is given as an 
exemplary MR-Sequence as you can see in Figure 25. Table XIII displays the 
corresponding mathematical analysis. 
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4.2.2.1 Single Patient 
 
Figure 17: Follow-up of Patient G-25 in T1-Sequence 
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Table V: Results from mathematical Analysis of Patient G-25’s Histograms 
from T1-Sequence during Follow-up 
  
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 3,05 3,05 3,05 3,05 3,05
Total Pixel-Count 3038 4718 25530 33286 15272
Total Volume (mm³) 9.271 14.398 77.911 101.581 46.606
Maximum Pixel-Count 334 653 2371 2652 892
Signalintensity-Peak 85 76 86 86 47
Mean Signalintesity 84,8 74,2 83,5 82,3 54,2
Standardization to CSF 1,56 1,37 1,54 1,52 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,84 4,84 4,84 4,84 4,84
Total Pixel-Count 818 1130 3349 5297 9566
Total Volume (mm³) 3.962 5.473 16.220 25.654 46.329
Maximum Pixel-Count 43 68 444 444 449
Signalintensity-Peak 119 16 91 91 50
Mean Signalintesity 118,2 41,2 88,4 82,9 62,3
Standardization to CSF 1,90 0,66 1,42 1,33 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,04 4,04 4,04
Total Pixel-Count 1614 1614 24799
Total Volume (mm³) 6.516 6.516 100.125
Maximum Pixel-Count 168 168 2392
Signalintensity-Peak 60 60 50
Mean Signalintesity 63,4 63,4 55,4
Standardization to CSF 1,14 1,14 1,00
After 
Radiation- 
and Chemo-
therapy
At 
Diagnosis
After 
Surgery
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Figure 18: Follow-up of Patient G-25 in T1 with Gadolinium Enhancement Sequence 
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Table VI: Results from mathematical Analysis of Patient G-25’s Histograms 
from T1 with Gadolinium Enhancement Sequence during Follow-up 
 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 2,22 2,22 2,22 2,22 2,22
Total Pixel-Count 10633 5116 26901 42650 8433
Total Volume (mm³) 23.619 11.364 59.756 94.740 18.732
Maximum Pixel-Count 298 357 2507 2595 605
Signalintensity-Peak 101 56 74 74 39
Mean Signalintesity 118,3 63,5 73,0 83,1 48,5
Standardization to CSF 2,44 1,31 1,50 1,71 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,84 4,84 4,84 4,84 4,84
Total Pixel-Count 5472 1214 4144 10830 10021
Total Volume (mm³) 26.502 5.880 20.070 52.451 48.533
Maximum Pixel-Count 167 76 480 500 395
Signalintensity-Peak 115 16 85 85 47
Mean Signalintesity 127,3 42,9 84,8 101,6 63,8
Standardization to CSF 1,99 0,67 1,33 1,59 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,04 4,04 4,04 4,04
Total Pixel-Count 2943 986 3929 22102
Total Volume (mm³) 11.882 3.981 15.863 89.236
Maximum Pixel-Count 131 57 131 2105
Signalintensity-Peak 108 55 108 47
Mean Signalintesity 121,2 61,5 106,2 52,7
Standardization to CSF 2,30 1,17 2,02 1,00
After 
Radiation- 
and Chemo-
therapy
At 
Diagnosis
After 
Surgery
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Figure 19: Follow-up of Patient G-25 in T2 Sequence 
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Table VII: Results from mathematical Analysis of Patient G-25’s Histograms 
from T2-Sequence during Follow-up 
 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 3,37 3,37 3,37 3,37
Total Pixel-Count 6633 26458 33091 8121
Total Volume (mm³) 22.348 89.141 111.488 27.361
Maximum Pixel-Count 1809 483 1938 3465
Signalintensity-Peak 255 154 255 255
Mean Signalintesity 211,8 174,1 181,6 230,9
Standardization to CSF 0,92 0,75 0,79 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,84 4,84 4,84 4,84 4,84
Total Pixel-Count 7436 818 39150 47404 11482
Total Volume (mm³) 35.969 3.957 189.373 229.299 55.540
Maximum Pixel-Count 3756 42 870 3756 185
Signalintensity-Peak 255 10 127 255 200
Mean Signalintesity 224,8 39,9 133,7 146,4 181,9
Standardization to CSF 1,24 0,22 0,73 0,80 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,04 4,04 4,04 4,04 4,04
Total Pixel-Count 118 1388 27993 29499 33150
Total Volume (mm³) 477 5.612 113.175 119.264 134.024
Maximum Pixel-Count 7 65 1112 1114 1420
Signalintensity-Peak 134 208 98 98 172
Mean Signalintesity 113,2 192,6 107,9 111,9 162,8
Standardization to CSF 0,70 1,18 0,66 0,69 1,00
After 
Radiation- 
and Chemo-
therapy
At 
Diagnosis
After 
Surgery
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Figure 20: Follow-up of Patient G-25 in T2 Flair Sequence 
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Table VIII: Results from mathematical Analysis of Patient G-25’s Histograms 
from T2 Flair-Sequence during Follow-up 
 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 3,37 3,37 3,37 3,37
Total Pixel-Count 9443 76159 85602 21727
Total Volume (mm³) 31.815 256.590 288.405 73.201
Maximum Pixel-Count 482 2478 2496 628
Signalintensity-Peak 135 153 153 18
Mean Signalintesity 133,8 147,0 145,6 36,3
Standardization to CSF 3,68 4,05 4,01 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,84 4,84 4,84 4,84 4,84
Total Pixel-Count 5976 868 45696 52540 11664
Total Volume (mm³) 28.907 4.199 221.037 254.142 56.420
Maximum Pixel-Count 373 33 1172 1183 315
Signalintensity-Peak 167 13 130 130 17
Mean Signalintesity 163,4 40,0 139,6 140,6 36,3
Standardization to CSF 4,51 1,10 3,85 3,88 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,04 4,04 4,04 4,04 4,04
Total Pixel-Count 53 899 46496 47448 25902
Total Volume (mm³) 214 3.635 187.982 191.831 104.721
Maximum Pixel-Count 6 72 1500 1500 1812
Signalintensity-Peak 131 51 119 119 16
Mean Signalintesity 133,6 53,4 121,7 120,4 29,2
Standardization to CSF 4,58 1,83 4,17 4,13 1,00
After 
Radiation- 
and Chemo-
therapy
After 
Surgery
At 
Diagnosis
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4.2.2.2 Summary 
 
Figure 21: Mean Histogram from T1-Sequence during Follow-up 
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Table IX: Results from mathematical Analysis of the mean Histograms from 
T1-Sequence during Follow-up 
 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,29 4,29 4,29 4,29 4,29
Total Pixel-Count 1696 4221 35651 41567 12701
Total Volume (mm³) 7.273 18.107 152.926 178.306 54.482
Maximum Pixel-Count 174 198 1263 1385 600
Signalintensity-Peak 85 33 79 79 53
Mean Signalintesity 82,0 51,7 72,5 70,8 52,1
Standardization to CSF 1,57 0,99 1,39 1,36 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,06 4,06 4,06 4,06 4,06
Total Pixel-Count 7009 15735 5480 28224 14078
Total Volume (mm³) 28.443 63.850 22.236 114.529 57.126
Maximum Pixel-Count 147 850 149 850 724
Signalintensity-Peak 127 46 91 46 50
Mean Signalintesity 121,3 54,8 102,2 80,5 61,2
Standardization to CSF 1,98 0,89 1,67 1,32 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 3,95 3,95 3,95 3,95 3,95
Total Pixel-Count 3145 6599 9519 19263 12997
Total Volume (mm³) 12.434 26.090 37.638 76.162 51.389
Maximum Pixel-Count 159 355 291 381 651
Signalintensity-Peak 76 28 109 79 51
Mean Signalintesity 90,0 43,2 93,7 75,8 56,6
Standardization to CSF 1,59 0,76 1,66 1,34 1,00
After 
Radiation- 
and Chemo-
therapy
At 
Diagnosis
After 
Surgery
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Figure 22: Mean Histogram from T1 with Gadolinium Contrast Enhancement during Follow-
up 
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Table X: Results from mathematical Analysis of the mean Histograms from 
T1 with Gadolinium Contrast Enhancement during Follow-up 
 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 2,54 2,54 2,54 2,54 2,54
Total Pixel-Count 13260 9742 31697 54700 12042
Total Volume (mm³) 33.617 24.699 80.358 138.674 30.529
Maximum Pixel-Count 221 486 1372 1837 630
Signalintensity-Peak 88 68 69 69 42
Mean Signalintesity 116,2 67,6 68,6 80,0 51,4
Standardization to CSF 2,26 1,32 1,34 1,56 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 3,82 3,82 3,82 3,82 3,82
Total Pixel-Count 9702 13109 8455 31266 13778
Total Volume (mm³) 37.096 50.126 32.331 119.553 52.682
Maximum Pixel-Count 238 422 229 491 578
Signalintensity-Peak 127 47 85 47 46
Mean Signalintesity 121,4 63,1 74,4 84,2 53,0
Standardization to CSF 2,29 1,19 1,40 1,59 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 3,89 3,89 3,89 3,89 3,89
Total Pixel-Count 4417 6653 6869 17938 12416
Total Volume (mm³) 17.198 25.908 26.746 69.852 48.347
Maximum Pixel-Count 93 292 366 427 570
Signalintensity-Peak 119 24 97 97 48
Mean Signalintesity 125,5 46,3 89,7 82,4 54,5
Standardization to CSF 2,30 0,85 1,65 1,51 1,00
After 
Radiation- 
and Chemo-
therapy
At 
Diagnosis
After 
Surgery
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Figure 23: Mean Histogram from T2-Sequence during Follow-up 
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Table XI: Results from mathematical Analysis of the mean Histograms from 
T2-Sequence during Follow-up 
 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,12 4,12 4,12 4,12 4,12
Total Pixel-Count 9863 1393 25917 37173 15363
Total Volume (mm³) 40.623 5.737 106.744 153.104 63.277
Maximum Pixel-Count 150 62 418 504 815
Signalintensity-Peak 255 102 153 153 255
Mean Signalintesity 163,1 102,0 148,8 150,9 174,5
Standardization to CSF 0,93 0,58 0,85 0,86 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,27 4,27 4,27 4,27 4,27
Total Pixel-Count 8830 9318 11465 29613 16197
Total Volume (mm³) 37.688 39.768 48.931 126.387 69.128
Maximum Pixel-Count 736 433 251 1190 226
Signalintensity-Peak 255 255 119 255 163
Mean Signalintesity 176,0 193,4 136,8 166,3 169,1
Standardization to CSF 1,04 1,14 0,81 0,98 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 3,90 3,90 3,90 3,90 3,90
Total Pixel-Count 5158 6535 13473 25167 15684
Total Volume (mm³) 20.109 25.480 52.530 98.119 61.147
Maximum Pixel-Count 103 498 171 516 267
Signalintensity-Peak 156 255 141 255 204
Mean Signalintesity 164,0 165,3 140,2 151,6 179,3
Standardization to CSF 0,91 0,92 0,78 0,85 1,00
After 
Radiation- 
and Chemo-
therapy
At 
Diagnosis
After 
Surgery
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Figure 24: Mean Histogram from T2 Flair-Sequence during Follow-up 
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Table XII: Results from mathematical Analysis of the mean Histograms from 
T2 Flair-Sequence during Follow-up 
 
 
4.2.2.3 Non-Glioblastoma 
Patient G-8 represents one of the four patients in our study group that did not 
suffer from GBM (see Table II). In this patient a brain metastasis, deriving from 
bronchial cancer, could be diagnosed as the cause of disease. 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,43 4,43 4,43 4,43 4,43
Total Pixel-Count 8783 1561 45886 56230 16388
Total Volume (mm³) 38.878 6.909 203.104 248.891 72.537
Maximum Pixel-Count 256 45 923 1148 438
Signalintensity-Peak 144 126 140 140 17
Mean Signalintesity 141,2 104,6 142,6 141,3 34,4
Standardization to CSF 4,10 3,04 4,14 4,10 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,47 4,47 4,47 4,47 4,47
Total Pixel-Count 13381 5298 22447 41126 13858
Total Volume (mm³) 59.825 23.687 100.357 183.869 61.957
Maximum Pixel-Count 921 142 487 927 450
Signalintensity-Peak 255 15 130 255 17
Mean Signalintesity 159,2 75,0 130,6 132,8 36,9
Standardization to CSF 4,32 2,03 3,54 3,60 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 4,09 4,09 4,09 4,09 4,09
Total Pixel-Count 8140 4874 20580 33593 14148
Total Volume (mm³) 33.275 19.923 84.128 137.326 57.837
Maximum Pixel-Count 235 255 340 574 469
Signalintensity-Peak 136 8 146 136 17
Mean Signalintesity 137,9 49,1 139,4 126,0 36,5
Standardization to CSF 3,77 1,34 3,82 3,45 1,00
After 
Radiation- 
and Chemo-
therapy
At 
Diagnosis
After 
Surgery
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Figure 25: Follow-up of Patient G-8 in T1 with Gadolinium Contrast Enhancement Sequence 
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Table XIII: Results from mathematical Analysis of Patient G-8 from T1 with 
Gadolinium Contrast Enhancement during Follow-up 
 
 
4.2.3 Summary Analysis – Overview 
Tables XIV-XVI give a clear overview about the three most meaningful aspects of 
our mathematical analysis, the SI-peak, the mean SI and the standardized mean 
SI, calculated from all patients of this study. Emphasis is placed on the 
comparison between active tumor and necrosis in the different sequences and the 
summarized whole lesion. 
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 2,00 2,00 2,00 2,00
Total Pixel-Count 19913 27780 47693 4394
Total Volume (mm³) 39.826 55.560 95.386 8.788
Maximum Pixel-Count 1488 3195 3249 347
Signalintensity-Peak 80 66 66 42
Mean Signalintesity 83,0 66,1 73,1 52,9
Standardization to CSF 1,57 1,25 1,38 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 5,72 5,72 5,72 5,72
Total Pixel-Count 6749 4435 11184 7136
Total Volume (mm³) 38.618 25.377 63.995 40.833
Maximum Pixel-Count 544 203 544 605
Signalintensity-Peak 107 79 107 49
Mean Signalintesity 113,3 73,6 97,5 54,9
Standardization to CSF 2,06 1,34 1,78 1,00
Tumor Necrosis Edema Whole Lesion CSF
Volume of 1 Pixel (mm³) 2,89 2,89 2,89
Total Pixel-Count 1092 1092 3293
Total Volume (mm³) 3.157 3.157 9.521
Maximum Pixel-Count 51 51 199
Signalintensity-Peak 156 156 51
Mean Signalintesity 152,9 152,9 57,1
Standardization to CSF 2,68 2,68 1,00
After 
Radiation- 
and Chemo-
therapy
At 
Diagnosis
After 
Surgery
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Table XIV: SI-Peak of all Sequences at different Time Points calculated from 
all Patients of this Series 
 
 
Table XV: Mean Signalintensity of all Sequences at different Time Points 
calculated from all Patients of this Series  
 
 
 
T1 T1 + Gd T2 T2 Flair
Tumor 85 88 255 144
Necrosis 33 68 102 126
Tumor 127 127 255 255
Necrosis 46 47 255 15
Tumor 76 119 156 136
Necrosis 28 24 255 8
79 69 153 140
46 47 255 255
79 97 255 136
After 
Radiation- 
and Chemo-
therapy
After Surgery
At Diagnosis
After Surgery
After Radiation- and Chemoth.
Whole Lesion
Signalintensity-Peak
At Diagnosis
T1 T1 + Gd T2 T2 Flair
Tumor 82,0 116,2 163,1 141,2
Necrosis 51,7 67,6 102,0 104,6
Tumor 121,3 121,4 176,0 159,2
Necrosis 54,8 63,1 193,4 75,0
Tumor 90,0 125,5 164,0 137,9
Necrosis 43,2 46,3 165,3 49,1
70,8 80,0 150,9 141,3
80,5 84,2 166,3 132,8
75,8 82,4 151,6 126,0
After Surgery
After Radiation- and Chemoth.
Mean Signalintensity
At Diagnosis
After Surgery
After 
Radiation- 
and Chemo-
therapy
Whole Lesion
At Diagnosis
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Table XVI: Standardized mean SI of all Sequences at different Time Points 
calculated from all Patients of this Series 
 
 
4.2.4 Volume Changes during Follow-up 
By multiplying the total pixel-counts of the different lesions with its particular pixel-
size, we were able to calculate the exact volume of each area that we have 
rendered. Figure 26 exemplary shows the course of disease of a single patient 
(G-25), by illustrating a volumetric development for the whole lesion, as well as the 
different subunits of tumorous tissues during the different time points and for all 
MR-Sequences. 
The second image in this section, Figure 27, depicts the mean volume changes 
during therapy in all MR-Sequences, calculated from all patients of the study group 
(except the non-glioblastomas). As the previous image does, it also compares the 
whole lesion with its three subunits active tumor, necrosis and edema. 
T1 T1 + Gd T2 T2 Flair
Tumor 1,57 2,26 0,93 4,10
Necrosis 0,99 1,32 0,58 3,04
Tumor 1,98 2,29 1,04 4,32
Necrosis 0,89 1,19 1,14 2,03
Tumor 1,59 2,30 0,91 3,77
Necrosis 0,76 0,85 0,92 1,34
1,36 1,56 0,86 4,10
1,32 1,59 0,98 3,60
1,34 1,51 0,85 3,45
After Surgery
After Radiation- and Chemoth.
Standardized Signalintensity
At Diagnosis
After Surgery
After 
Radiation- 
and Chemo-
therapy
Whole Lesion
At Diagnosis
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4.2.4.1 Single Patient 
 
Figure 26: Volume Changes during Follow-up in Patient G-25 for all Sequences. Comparison  
of the whole Lesion to the three Subunits (Active Tumor, Necrosis and Edema). 
Results 
69 
4.2.4.2 Summary 
 
Figure 27: Volume Changes during Follow-up in the Summary, for all Sequences. 
Comparison of the whole Lesion to the three Subunits (Active Tumor, Necrosis and Edema). 
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4.2.5 Assessment of Progression and Response 
This section illustrates four different possible courses of disease on the basis of 
the individual volume development during treatment and follow-up. Figure 28 
shows how the volume of the whole lesion and the different pathologic subunits 
develops in a patient that clearly suffers from real tumor recurrence, after receiving 
surgery, RT and chemotherapy (G-17). In Figure 29 the volume development of a 
patient that shows pseudoprogression, after receiving surgery, RT and 
chemotherapy (G-12), is depicted. Figure 30 displays the course of disease from 
a patient with stable disease (G-7), whereas the response shown in Figure 31 is 
rather questionable due to the contradictory volume development of the three 
subunits (G-23). 
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4.2.5.1 Real Progression in T1 with Gadolinium Contrast Enhancement 
 
Figure 28: Volume Development during different Time points in a Patient that suffers from 
real Tumor Progression after receiving Surgery and Radiation- and Chemotherapy (G-17) 
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4.2.5.2 Pseudoprogression in T1 with Gadolinium Contrast Enhancement 
 
Figure 29: Volume Development during different Time Points in a Patient that shows 
questionable Progression after receiving Surgery and Radiation- and Chemotherapy (G-12) 
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4.2.5.3 Stable Disease in T1 with Gadolinium Contrast Enhancement 
 
Figure 30: Volume Development during different Time Points in a Patient that shows stable 
Disease after receiving Surgery and Radiation- and Chemotherapy (G-7) 
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4.2.5.4 Questionable response in T1 with Gadolinium Contrast Enhancement 
 
Figure 31: Volume Development during different Time Points in a Patient that shows 
questionable Response after receiving Surgery and Radiation- and Chemotherapy (G-23) 
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5 Discussion 
5.1 Evaluation of Software and Segmentation Methods 
DoctorEye represents an user-friendly segmentation software which allowed us to 
perform relatively fast annotations of different data sets at the same time, with a 
high level of accuracy. Our lively cooperation with the developers of FORTH 
enabled us to impact the platform’s updates and designing. Over the two years of 
our research project our suggestions and input for improvement primarily focused 
on the software’s practical handling and its applicability in the clinical routine. 
Additionally we came up with the idea to create histograms based on the 
annotated areas, a suggestion that was immediately implemented into the 
software by the developers. 
During the last two decades there have been multiple attempts to analyze medical 
images using modern information technologies. Currently there are several other 
existing image-annotation platforms, including VANO [109], CMAS [90], Hybrid 
System [99], Annotor [2], Amiravis [1], Itk-SNAP [4] and many more [3, 5]. Even if 
these various tools have been developed to speed up the process of data analysis 
for different biomedical applications, still most of the open access solutions require 
extensive engineering skills to understand their sophisticated user interface. In 
contrast to DoctorEye their whole design rarely takes the actual clinical user’s 
needs or the specific features required in the clinical setting and the goal to derive 
qualitative and quantitative diagnostic information into account [126]. DoctorEye 
on the other hand was found to be an impressively user-friendly segmentation 
software that allowed us to simultaneously perform fast annotations of different 
data sets, with a high level of accuracy. After using the software over a large 
number of datasets, in our hands, the platform’s environment appeared very 
intuitive and easy to handle. In fact, our experience over the complete study period 
confirmed our initial impression that only basic knowledge of annotation/simulation 
processes is required to start up using this system effectively. 
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The main advantages of DoctorEye in comparison to already available image-
processing tools have already been pointed out by Skounakis et al. and include 
the following [49, 126]:  
 Open access software with free distribution for testing and no need for 
registration or activation. 
 Easy to use, due to the platform’s design as a GUI environment with 
standard menus and buttons. Its interface is flexible and can be easily 
customized to different viewing setups by adjusting the width and height of 
the thumbnail and the main window by sliding the window separator bar. In 
consequence, the user can actively alter the number of the thumbnails 
visible on the screen as well as the size of the selected image. The 
resolution and size of the user’s screen are also taken into account for 
ensuring an optimal representation. 
 Fast and accurate delineation of tumors in large number of 3D tomographic 
datasets, especially in areas with complicated shapes, facilitated by manual 
and semiautomatic segmentation techniques combined with integrated 
correction tools. The fast operation-time is realizable due to the fact that the 
applied algorithms are fully integrated in the platform and run “on the fly” 
and not as calls to external programs. 
 The ability to set multiple labels that allow the user to annotate and manage 
multiple areas of interest in each selected slide at the same session. 
 The user is permitted to view the effects of the features that are being 
implemented in the selected medical image while experimenting with 
various parameters. 
 More importantly the clinical driven modular design and functionality, 
ensuring that the software has the potential to be implemented in routine 
clinical practice. 
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 Additionally to “standard” features like annotation/segmentation and 3D 
visualization the flexible architecture of DoctorEye provides the opportunity 
for easy incorporation of more specific and sophisticated plug-ins that can 
empower the clinician to use modern technologies for enhanced diagnosis 
and therapy design. An exemplary plug-in enables the user to do 
computational “in-silico” models of cancer growth and simulation algorithms 
of therapy response in order to provide a future integrated platform for 
modeling assisted therapy decision making. 
As a tool for predictive oncology research and clinical work DoctorEye can allow 
cancer modellers to easily plug in their models for cancer growth and therapy 
simulation. Moreover, besides being a tool for analyzing cancer imaging data, at 
the same time it could also serve as a validation environment for clinicians, where 
the simulation predictions can be compared with the actual therapy outcome, in 
order to achieve a global optimization of the modeling modules.  
The final assessment of the methods engaged indicates that the “Magic Wand” 
method provides great ease of use and is more applicable to medical images, 
especially when the gray level profile of the tumor is very homogenous and there 
is enough contrast to the surrounding tissues. In more problematic settings the 
software offers sophisticated solutions. If the regions of interest exhibit a high 
structural complexity, the “Zoom In” mode can facilitate the rendering enormously 
by magnifying the investigated area. If the result obtained by only using the Magic 
Wand is not satisfactory, manual refinement can be performed by engaging the 
correction tools “pencil and eraser”, to achieve a most precise result, as illustrated 
in Figure 11 and 12. 
The accuracy of this technology was confirmed by the well-recognized expert in 
neuroradiology Prof. Reith from the University of the Saarland. Our results 
regarding the delineation of different pathologic areas in different MRI scans were 
in total accordance with the expert’s assessment, clearly demonstrating that a 
higher accuracy cannot be achieved by any other segmentation method. However, 
it has to be acknowledged that even with DoctorEye the evaluation of very 
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complex structured lesions with a highly heterogeneous distribution of SI still 
requires a high amount of patience and time. An untrained user most likely 
requires a processing time of more than 15 minutes (see results 4.1.1) for one 
sequence, respectively 20 slices. Such time consuming evaluations would prove to 
be still very inexpedient for a clinician’s tight scheduled daily workflow. Although 
the time necessary to get the software ready-to-use, to up-load large datasets und 
to evaluate and safe the results is almost invincible fast, the use of the “Magic 
Wand” algorithm is yet too time-consuming and not practicable to be utilized in 
clinical daily routine.  
Apart from still being clinically unsuitable due to the time consuming evaluation 
processes, manual- and largely semiautomatic-segmentation techniques have an 
additional drawback. According to Weltens et al. inter-observer variability in brain 
tumor delineation with different physician specialties performing contours in both 
CT alone and CT with MRI ranged between 9-32% [155]. Mazzara et al. showed 
that the intra- and inter-rater variability performing manual segmentations on MRI 
scans of patients with gliomas varies significantly, being reported to be 
approximately 20%±16% and 28%±12%, respectively [98].  
Following our experience with DoctorEye a more expeditious technique has to be 
implemented to make the method applicable for the routine medical environment 
as well as to reduce operator-dependency during evaluation. Either an automatic 
or an advanced semi-automatic methodology probably can achieve this. Kaus 
et al. reported in 2001 that their technique of automated tumor segmentation in 
MR images performed essentially faster than the compared technique of manual 
rendering, which is in principle comparable to our software [74]. 
Such an automatic segmentation technique should on the one hand provide the 
option to accurately delineate complex pathologic areas and on the other hand 
speed up the operating time in treatment planning, by keeping the need for user 
interaction as low as possible. Additionally, the measurement protocol should be 
standardized and reproducible, so that it can be applied in any clinical environment 
independent from the clinician’s prior training. 
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The publication mentioned above by Mazzara et al. reported about the evaluation 
of two different segmentation methods, an automatic and a semiautomatic one. 
Validation was performed by the comparison to manual segmentation [98]. The 
fact that all the study subjects suffered from primary brain cancer (glioma) but not 
specifically from GBM slightly reduces the comparability of these results with our 
observations. This is related to the structural complexity often found with GBM in 
medical images, which frequently affects accuracy and operation-time. Mazzara 
et al. evaluated the k-nearest neighbor (kNN) system, as a representative of 
operator-assisted semiautomatic segmentation, and the knowledge-guided (KG) 
method, as a representative of fully automated tumor volume measurement. While 
the kNN system requires the user to select training data from each MRI slice, the 
KG method does not need any user input and has therefore in principle no 
variability in its output. Both methods have been successfully studied and clinically 
used for improved accuracy of tumor volume measurements since almost 25 years 
[40, 145]. From the three methods investigated the KG method required the least 
operation time, in average 8,2 minutes per patient, followed by the kNN system, 
requiring 20 minutes per patient. The manual method proved to be the slowest and 
was recorded to consume in average 30 minutes for the evaluation of an individual 
patient. Relevant for our studies on GBM is the fact that in comparison to the kNN 
method the KG method performed poorly for glioma cases, which showed Gd-
enhancement with non-enhancing cystic necrotic centers. This is considered to be 
due to the need of user input for the initial selection of training pixel data in the 
kNN method. As glioblastoma often exhibit cystic necrotic centers, the technique 
described by Mazzara appears to be inappropriate to provide valid volume data. 
Also the KG method does not segment non-enhancing tumors. In conclusion the 
two methods described by Mazzara lack accuracy compared to the manual 
assessment of radiation oncologists, but are superior in terms of reproducibility 
and processing time. 
Kumar M. et al proposed in 2011 another automatic seeded region growing 
method to segment brain tumors in 2 D MR images [82]. However, while their 
results indicate that fast and accurate segmentation by automatically finding the 
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seed points for the region growing method can be achieved, the tumors analyzed 
in this study appear to be structurally less complex as the GBMs analyzed by us. 
Before this approach is not validated in lesions comparable to glioblastoma, the 
value of this technique for our purposes cannot be judged. 
In 2011 Mohd Saad et al. applied an automated region growing technique on 
Diffusion-weighted MRI, focusing not only on brain tumors but also on acute 
infarction, haemorrhage and abscesses [102]. First, region splitting and merging 
was performed to subdivide the image with preservation of the pathological area. 
Second, the histogram threshold was used to find the optimal intensity threshold 
value, which is the prerequisite for the automatic selection of the initial seed-point. 
The results of their study showed that their automatic solution of region growing 
provided comparable results with the semiautomatic segmentation in terms of 
accuracy. However, their sample-set again was highly heterogeneous, consisting 
not only of glioblastoma but also including 3 cases of abscesses, 4 haemorrhage, 
11 acute infarction and 2 tumors with unmentioned histology. As discussed with 
the study before this method needs to be validated on GBM cases before its value 
in GBM diagnostics can be assessed reliably. Choubey and Agrawal published 
their results in 2012, also describing an automatic segmentation method based on 
the region growing, the so called “random walk movement”. Once more in this 
approach the seed point is automatically calculated, following a skull removal to 
prevent falsified seed point selection. As proposed, this method ought to be 
effective in 2 dimensional MRI, but the accuracy depends on the lesion’s shape 
and size (very small tumors fail to be detected) [39]. 
Another frequently used segmentation method is the so called “fuzzy connectivity” 
or “fuzzy connectedness algorithm”. Through the fuzzy process the fuzzy 
connectedness algorithm joins related pixels in the investigated region despite 
inhomogeneity of signal intensities or gradient variations [61]. This concept of 
fuzziness was firstly introduced by Rosenfeld in 1970, as affirmed by Harati et al. 
[61, 120]. Just as with Region-Growing, the selection of the initial seed point in this 
technique is a substantial and time-consuming task and inevitably requires an 
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operator. Therefore Harati V. et al. developed a fully automatic segmentation 
procedure with the purpose to eliminate user interactions in the seed point 
selection and to improve the performance of the general fuzzy connectedness 
[61]. To automatically select the seed point and to execute the tumor segmentation 
algorithm in average an operation time of 30 s and 2 min was consumed [61]. The 
authors claim that this procedure does not go at the expanse of accuracy. To 
confirm this assertion, they compared their method with the general fuzzy 
connectedness, represented in 1996 by Udupa and Samarasekera [142]. Almost 
all recent approaches in the field of fuzzy connectedness are based on the 
principles of that specific algorithm. The criteria values revealed that the 
performance of the proposed method is superior to that of general fuzzy 
connectedness in all investigated cases. In a more topical study from 2006, 
Pednekar et al. proposed one of the state-of-the-art approaches related to the 
improved generalized fuzzy connectedness [108]. An important drawback of this 
study in comparison to the study mentioned before lies in the small amount of data 
that has been investigated and the fact that seed points were selected manually, 
whereas in the aforementioned method seed points were selected automatically. 
One advantage, however, is that the method, according to Pednekar et al., can be 
applied to different types of radiologic images such as MR, CT and infrared data 
[108]. This is attributable to the dynamic tuning of weights of affinity components 
as required in the fuzzy connectedness algorithm, whereas in the method 
proposed by Harati V. et al. constant optimized weights are used, which is only 
applicable to brain MR images [61]. 
Another recently proposed approach for fully automatic brain tissue segmentation 
was published by Bauer S. et al. in 2011. This group is part of the ContraCancrum 
project and obtained images of 10 study patients from the ContraCancrum brain 
tumor database [22]. In this study the combination of the Support Vector machine 
classification (SVM) using multispectral intensities and textures with subsequent 
hierarchical regularization based on Conditional Random Fields showed promising 
results. According to the authors, there is a strong dependency of most voxel 
labels on their neighbors, a statement that is in disagreement with the assumption 
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that the data in MR images are independent and identically distributed (iid). Bauer 
and coworkers engaged the Conditional Random Field (CRF) method to respect 
these spatial relationships. The way of applying the CRF was inspired by a study 
performed by Lee et al. in 2008 [88]. As in our study, Bauer et al. subdivided the 
tumor area hierarchically into necrotic, active and edematous tumor portions, 
besides generally distinguishing between normal healthy and tumor region. By 
using the Insight Toolkit for Segmentation and Registration (ITK) they were able to 
incorporate the preprocessing completely with the SVM classification and CRF 
regularization components [70]. Quantitative evaluation of the tumor tissue 
segmentation again was performed with the ground truth defined by manual 
segmentation, using the dice similarity coefficient. As a result it was shown that 
this coefficient is evidently a worse measure when no hierarchical regularization is 
applied. The operation time for the segmentation algorithm mainly depends on the 
size of the image dataset and on the complexity of the SVM optimization. It 
performs obviously faster than our approach, taking between 20 and 120 seconds 
on a single CPU (Central Processing Unit) running at 2,33 GHz. However, it has to 
be taken into account that preprocessing was not included in this estimation. 
Compared to other studies, like Corso et al [42] and Wels et al. [154], dice 
similarity coefficients for the gross tumor volume are in a similar range, but 
different data-sets were used. Additionally, although in this approach differentiation 
into tumor and healthy subsets was performed, the operation time was shorter. In 
terms of accuracy the results are comparable to manual segmentation, with the 
advantage of excluding biased subjectively of the operators in longitudinal studies. 
Since differentiating the tumor into its subunits causes additional difficulties, the 
dice similarity coefficients for the subunits are lower than for the gross tumor 
volume. In conclusion, this new approach has great potential, as its operation time 
appears to be acceptable for the clinical workflow and by including the CRF based 
hierarchical regularization, improved conformity with the ground truth was 
achieved. 
Finally, the incorporated adaptive active contour algorithm, developed by ICS 
group of FORTH, has shown promising results in closely following clinical 
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annotations, as demonstrated by Farmaki et al. [50]. As described by Skounakis 
et al., this method is non intuitive, implying that the user might find it difficult to 
interpret the physical meaning of the related parameters and to predict the optimal 
values to be selected and adjusted individually for every tumor case [127]. 
5.2 Assessment of Progression and Response 
Since 1990 the MacDonald criteria [96], based on measurable changes in 
contrast-enhancing lesions on MR scans, have been the standard approach for 
measuring response or progression in patients with malignant glial tumors. In 2010 
the RANO Working Group suggested new criteria [159] that indicated the 
limitations of the above mentioned approach and added additional aspects. 
Nevertheless, neither a concrete assessment of changes in T2-/Flair-sequence is 
required nor is a volumetric measurement of the contrast enhanced lesions 
suggested. The dependence of the contrast enhancement in the T1 sequence on 
many parameters is another source of inaccuracy of these criteria [151]. In 
consequence it has to be acknowledged that the currently available guidelines are 
still insufficient and lack in accuracy [24]. Therefore, the process of analyzing the 
follow-up of individual patients with malignant gliomas requires more research and 
improvement of diagnostic procedures to achieve better understanding and 
facilitate individualized treatment of this currently still fulminant and lethal disease.  
The lack of an established concept to follow tumor development and progression 
inspired us to search for an innovative approach of gaining tumor specific 
characteristics from routinely acquired MR images. The current routine to measure 
tumor size only by the product of the longest diameter and its longest 
perpendicular diameter in a single slice seems to be highly inappropriate, as 
glioblastoma tend to be very irregularly shaped. For that reason we decided to 
also incorporate a three dimensional volume measurement of the different 
tumorous tissues into our study. Furthermore, we applied our method not only on 
T1 Gd-MRI scans, but also on the other routinely acquired sequences, particularly 
T1 without contrast, T2 and T2 Flair. As mentioned above, these sequences do 
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not play any role in the official criteria and clinically just serve for visual 
interpretation performed by neuroradiologists. However, it was our goal to extract 
as much information from standardly available images as possible. Our findings 
support the observation that by measuring volumes and segmenting the tumor in 
different sequences active tumor-tissue, necrotic areas and edema may be 
distinguished ideally by using the histograms of the signal intensities, which differ 
within the tumor and vary strongly in most sequences. Using combinations of 
histograms from different sequences the tumor can be described in a much better 
way than by calculating solely the tumor volume. 
It is important to state that, despite recent diagnostic and therapeutic 
achievements, patients with glioblastoma have a poor prognosis and oncologists 
and neuroradiologists have to face multiple diagnostic problems. Early diagnosis 
of progressive disease (PD) and its distinction from different neuroradiologic 
phenomena, particularly radiation necrosis (RN), pseudoprogression (PP) and 
pseudoresponse (PR) is crucial since these entities request different treatment 
approaches [31]. To this end, several imaging techniques recently have been 
evaluated with varying results (see 5.2.1 Different Imaging Modalities) [10].  
Texture analysis and feature extraction from images has been a long standing 
topic of radiologic research [58], reviving in some kind of a “texture renaissance” 
during the last decade [73]. Obviously this trend is related to the steep increase in 
digital technology and storage capability, computerized image management and 
the established acceptance of computer-aided diagnosis, engaging automatic or 
semiautomatic image analysis tools [140]. Stated by Kassner and Thornhill, Lerski 
et al. were the first to introduce MR image texture analysis for the characterization 
of intracranial tissues, the identification of brain tumors and the differentiation 
between them [73, 89]. What Tourassi calls a “texture signature” refers to the idea 
of a reproducible and robust method of extracting pathologic findings from 
radiologic images, while being refractory to possible bias caused by individual 
attitude, beliefs, preconceptions, expectations or fatigue [140]. Especially in the 
evaluation of malignant brain tumors texture analysis seems to be a reasonable 
Discussion 
85 
approach due to the limitations of image interpretation. With the basic 
mathematical method which we have engaged in our study we tried to obtain such 
a “texture signature”, which may provide a worthwhile way to improve image 
analysis and to reveal new tumor-specific information that helps to distinguish 
between PD and the afore mentioned imaging phenomena. 
Our results, gained by the use of the DoctorEye software, indicate that the 
proposed innovative method of texture analysis can be a complementary 
diagnostic tool to differentiate various intracranial lesions from each other as well 
as to assess response to treatment or progression in malignant glioma. At the time 
we initiated our study to the best of our knowledge no information was available 
that histograms of signal intensities from MR images were used for the 
characterization of glioblastoma. This is probably caused by the lack of 
standardization in MRI technologies, which hampers the comparability of the 
results. 
Evaluating our results, the first thing we noticed was that at the time of diagnosis 
the histogram of all glioblastoma showed a bimodal distribution of signal intensities 
in T1 Gd-MRI sequence, with one peak each representing active tumor and 
necrosis. Figure 15 exemplarily illustrates our results from patient G-13 at the time 
of diagnosis. It is obvious that especially in the T1 Gd-MRI sequence the major 
part of the active tumor- and necrosis-area occupy different areas on the SI scale 
as well as their peaks do. As listed in Table III, the corresponding statistical values 
differ strongly from each other as well. The SI-peak of the active tumor is 93 on the 
SI scale and the mean SI 102,6, whereas for necrosis it is 63 and 63,8, 
respectively. These regularities of the SI distribution can also be found in the 
average histograms. Above all in the T1 Gd-MRI, but also in the other sequences, 
a clear distinction of the SI-peak and mean SI between active tumor and necrosis 
can be detected. Depending on the examined MR sequence, also edema can be 
discriminated easily either from active tumor or necrosis. 
Such similarities of the shape and the statistical values are seen during the course 
of disease in individual patients as well. This is valid for the images after surgery, 
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after radio- and chemotherapy and during the subsequent follow-up. 
Nevertheless, we are faced with the problem of insufficient standardized 
procedures in the acquisition of MR images. To overcome this issue we 
normalized the mean SI of the vital tumor area and of the necrotic tumor area by 
relating them to the mean SI of the corresponding CSF, resulting in a clear 
difference between tumor and necrosis at all analyzed time points in T1, T1 Gd-
MRI and T2 Flair (Table XVI). According to our observations, it seems that the 
more the standardized mean value of SI for the “whole lesion” in T1 with contrast 
enhancement is increasing during follow-up in a single patient, the more likely the 
patient suffers from disease progression or tumor recurrence. If this value is going 
down, the more likely a tumor response or a stable disease can be diagnosed. 
Typically after surgery we find an increase of the standardized SI and after 
radiation- and chemotherapy a decrease. Patient G-17 illustrates the SI 
development as an example of a patient suffering from tumor recurrence. While 
the SI after surgery is increasing, it decreases after radiation- and chemotherapy, 
as explained. Nevertheless, during follow-up the tumor is recurring, revealed by 
the increase of volume, already shown in Figure 28. Simultaneously to this 
volume changes, also the values for the SI peak, mean SI and standardized SI are 
increasing, as demonstrated in Figures 32-34. In contrast patient G-7 illustrates 
the course of disease from a patient with stable disease. Figure 30 depicts the 
volume development of this patient during follow-up, indicating a state of stable 
disease by the absence of any volume increase. Consistently also the SI values of 
patient G-7 (SI peak, mean SI and standardized SI) do not show any 
augmentation during follow up, as depicted in Figures 35-37. 
This statistical distinctiveness is an ideal condition to develop an automatic 
segmentation algorithm, which would be the ideal advancement to increase the 
practicality of our approach. Therefore, we have involved Prof. Joachim Weickert 
from the Faculty of Mathematics and Computer Science at the Saarland University 
into our study. Prof. Weickert is an expert in the field of image processing and the 
head of the Mathematical Image Analysis Group (MIA) at the Saarland University. 
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He and his team are working on a more sophisticated, automatic segmentation 
method to improve the accuracy and reproducibility of the results of our 
measurements. 
 
Figure 32: Development of SI-Peak during Follow-up in a Patient that suffers from Tumor 
Recurrence (G-17) 
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Figure 33: Development of Mean-SI during Follow-up in a Patient that suffers from Tumor 
Recurrence (G-17) 
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Figure 34: Development of Standardized-SI during Follow-up in a Patient that suffers from 
Tumor Recurrence (G-17) 
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Figure 35: Development of SI-Peak during Follow-up in a Patient with stable Disease (G-7) 
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Figure 36: Development of Mean-SI during Follow-up in a Patient with stable Disease (G-7) 
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Figure 37: Development of Standardized SI during Follow-up in a Patient with stable Disease 
(G-7) 
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Currently studies focusing also on the topic of texture analysis in GBM images 
have been published, e.g. by Drabycz et al., Pope et al. and Najafi et al.. In 2010 
Drabycz et al. tried to noninvasively predict the MGMT methylation promotor 
status by texture analysis of MRI scans [46]. They could show that the ring 
enhancement on MR images from glioblastoma patients significantly correlated 
with an unmethylated MGMT promoter status. Nevertheless, their application of a 
space-frequency texture analysis did not deliver any valuable results [46]. 
Recently Pope et al. presented their results after testing the predictive value of 
apparent diffusion coefficient (ADC) histogram analysis, with the aim to 
prognosticate the progression-free survival (PFS) and overall survival (OS) in 
bevacizumab-treated patients suffering from recurrent GBM. In this attempt the 
histograms were computed from areas of enhancing tumor on T1 weighted post-
contrast images. By the combined interpretation of the mean ADC from the lower 
curve (ADC-L) and the mean lower curve proportion (LCP) a maximum specificity 
of 87 % for the prediction of progression-free survival was achieved [113]. Another 
topical approach was published by Najafi et al., trying to predict the response to 
bevacizumab treatment in patients with GBM [103]. Aspiring to extract significant 
statistical features especially from T1Gd-MRI, but also for T1-, T2- and T2 
Flair-weighted images, they applied signal decomposition and histogram analysis 
methods. Volume estimation was accomplished for areas of gadolonium-
enhancement, edema and necrosis. By comparing SI of T1-weigehted images and 
corresponding T1-postcontrast images they designed an elegant and innovative 
method for the normalization of the images and their grey levels. By analyzing the 
standard deviation of the grey matter histograms, it proved to provide a potentially 
significant tool to predict the response of GBM to bevacizumab treatment before it 
was initiated [103]. 
In future research the use of our technique especially for the discrimination of the 
radiologic phenomena described below has to be validated. It is our position that 
the extraction of information from routinely performed investigations has to be 
optimized and exhausted before creating the need for additional investigations, 
potentially at the expense of the patient’s physical- and the hospital’s 
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economical-well-being. Hereinafter current neuroradiologic approaches towards 
these issues will be outlined. Furthermore, the mentioned phenomena are 
described in more detail. 
5.2.1 Different Imaging Modalities 
Today neuroradiologic imaging is the major diagnostic modality for the evaluation 
of brain tumors. The T1 Gd-MRI sequence is usually sufficient to suggest a brain 
tumor, while further sequences may already provide detailed information that 
indicates the specific tumor type. Currently there are several additional imaging 
modalities available, like magnetic resonance spectroscopy (MRS), diffusion 
weighted MRI (DWI), perfusion weighted imaging, positron emission tomography 
(PET), and single photon emission CT (SPECT). Nevertheless, to specify the 
diagnosis and to optimize the subsequent treatment strategy the acquisition of an 
adequate tissue sample by invasive procedures is essential. This will be acquired 
either at the time of the surgical resection of the tumor or by stereotactic biopsy, 
performed separately. 
With the innovative mathematical method of analyzing routine MRI scans 
proposed by us we sought to reveal new tumor-specific information in order to 
facilitate the description of the tumor’s development and possibly to differentiate 
between response to treatment and progressive disease. Furthermore, our 
approach could support the better identification of the different challenging 
radiologic phenomena like PP, PR and RN, described below. To this end our 
method is easily feasible in daily clinical care and, since it can provide results 
without additional imaging studies, it proves to be more cost-effective. 
Nevertheless it has to be validated to prove its effectiveness and justification to be 
a diagnostic tool on the basis of conventional MRI, which is increasingly seen 
critical. 
Concerning this matter Payer argues that conventional MRI is not sufficient to 
display the structural complexity, physiology and metabolism of GBMs. MRI may 
miss transformation and infiltration of healthy tissue [107]. Moreover, there is a risk 
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to misinterpret changes of contrast enhancement as progression or therapy 
response, even if PP, RN or PR represent the true cause of variation, or vice versa 
[107]. These limitations demand the introduction of more versatile procedures, 
imaging acquisition techniques on the one hand, which will be discussed in the 
following and image analysis techniques on the other hand, such as the one 
presented by us.  
Three MR-based techniques have been established lately, to achieve more 
precise assessment of tumor development, DWI, perfusion-weighted imaging and 
MRS. DWI represents a dynamic method to display areas of water diffusion, using 
the apparent diffusion coefficient (ADC), thereby revealing lower diffusion values 
especially in areas of ischemia and areas of high cellularity [41]. Hein et al. 
demonstrated in 2004 that DWI could serve as a helpful tool in the differentiation 
between tumor progression and treatment-induced imaging changes, as recurrent 
tumor typically has significantly lower ADC values than RN [64]. Another 
advantage comes with the fact that DWI in many institutions is part of standard 
neuroimaging and therefore does not generate additional costs. In addition, the 
processing time can be kept short with the use of fast imaging sequences (echo 
planer imaging) and an integrated ADC calculating software in the workstation 
[64]. As Payer states, the introduction of MR-diffusion analysis in the clinical 
routine could enable to better characterize edema, necrosis and active tumor 
[107]. Perfusion weighted imaging allows the illustration of intracranial 
hemodynamics by assessing regional cerebral blood flow and blood volume, 
typically revealing an elevated microcirculation in high grade brain tumors [41]. In 
a small study Hu et al. indicated in 2009 that the relative cerebral blood volume 
(rCBV) can differentiate between recurrence and posttreatment radiation effects 
with a high degree of accuracy. According to their observation, recurrent tumor 
typically exhibits an elevated rCBV, whereas treatment induced contrast 
enhancement shows a reduced rCBV [68]. These findings are supported by a 
study of Baraja et al. that demonstrated with 57 patients suffering from GBM that 
rCBV was significantly higher in the group of recurrent tumor than within the 
radiation necrosis group [16]. Nevertheless, a considerable overlap for this 
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parameter was noted between both groups, possibly due to the tumors 
heterogeneity. Therefore the notion seems reasonable that relative peak height 
(rPH), which proved to be more reliable, could also be helpful in the differentiation 
between recurrent GBM and radiation necrosis, thereby complementing the 
noninvasive investigations [16]. In 2010 Mangla et al. suggested that the survival 
of patients with glioblastoma, after receiving combined radiation- and 
TMZ-therapy, shows a negative correlation with the rCBV. The increase of 
posttreatment rCBV seemed to be a strong predictor of poor survival and vice 
versa, whereas the Gd-MRI based McDonald-criteria did not appear to be useful in 
such a setting [97]. Innovative approaches of analyzing perfusion values, as 
proposed by Tsien et al., might also facilitate the differentiation between 
progressive disease and pseudoprogression [141]. Nevertheless, these methods 
are not accurate enough to be the only decisive value for distinguishing tumor from 
PP or RN, as Clarke et al. concludes [41]. MRS on the other hand reveals 
biochemical information about the concentration of brain metabolites like choline 
(Cho), N-acetylaspartate (NAA), creatine and lactate, with special emphasis on the 
Cho/NAA ratio. As Clarke et al. reviewed, an elevated Cho/NAA ratio, caused by 
an elevation of the Cho peak and a decrease of the NAA peak, can indicate active 
tumor. A typical indicative of necrosis is the general flattening of all peaks, 
whereas the overlap of two peaks corresponds to lipids and lactate. Nevertheless 
the most commonly available type of MRS, single-voxel MRS, is restricted in its 
clinical use due to the large size of the voxels. Although the introduction of 
multivoxel MRS improved precision, the significant heterogeneity caused by the 
voxel’s size is still a problem. Moreover, the applicability is limited by the fact that 
the Cho/NAA ratio lacks in precision, as it may also be seen in the setting of 
significant inflammation or infection and therefore is not specific for progressive 
disease [41]. Nevertheless, in their review from 2012 Caroline and Rosenthal 
proposed that decreased Cho combined with a lipid or lactate peak indicates RN 
[31, 112]. In addition, recent literature provides studies that illustrate that sensitivity 
could be improved, if MRS was performed months after RT (89-100%), while the 
results were more specific if it was performed in weeks after treatment (100%) 
[104, 112, 168]. 
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Payer reports that nuclear investigation methods through PET-based imaging can 
help to display the metabolism of glucose and amino acids in malignant gliomas by 
the use of radiotracers. There has been extensive research on the value of PET as 
a tool to distinguish between PD and PP. Currently radiotracers like 
fluorodeoxyglucose ([18F]FDG), representing the glucose metabolism, as well as 
the amino acids methionine ([11C]MET) and fluorothymidine ([18F]FLT) and the 
amino acid analog fluorethyltyrosin ([18F]FET), representing cellular and vascular 
proliferation, are widely available tracers [54, 107, 153]. Caroline and Rosenthal 
state that tissue hypermetabolism, visualized by an increased radiotracer uptake, 
is associated with tumor recurrence [31]. This hypothesis is supported by the study 
from Chao et al. published in 2001, where [18F]FDG was 75% sensitive and 81% 
specific in distinguishing recurrent brain tumor from RN [36]. However, la Fougere 
et al. argue that the sensitivity of [18F]FDG, the most frequently used radiotracer, is 
significantly limited since many areas, such as the cerebral cortex, the basal 
ganglia, and the thalamus in the brain exhibit high physiologic glucose 
consumption, causing difficulties in the differentiation between tumor and normal 
brain. The same applies to the method’s specificity due to the accumulation of 
[18F]FDG in macrophages and inflamed tissue, hampering the delineation of active 
tumor additionally [83]. Inspired by the knowledge of the importance of amino acid 
metabolization for the proliferation of glioma, radiolabeled amino acids were 
introduced as PET tracers in 1982 [69, 72, 153]. Due to the limitations of [18F]FDG 
as a PET tracer considerable research projects have engaged radiolabled amino 
acids, aiming to find tracers with both improved sensitivity and specificity. Already 
in 1996 Wurker et al. presented their results on the methionin uptake in patients 
with low-grade gliomas treated with brachytherapy, which suggested that amino 
acid tracers might be superior in monitoring therapeutic effects [162]. Regardless 
of the phase of the cell cycle it was shown experimentally that tumor cells are 
capable of up regulating the expression of amino acid transporters in their cell 
membrane in order to increase the transmembrane amino acid influx, particularly if 
growth conditions deteriorate [122]. Different studies proved that the distribution of 
[11C]MET and [18F]FET in brain tumors is comparable [85], whereas the clinical 
availability of [18F]FET is superior due to its longer physical half life [153]. La 
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Fougere et al. concluded that both markers, [11C]MET and [18F]FET [83], hold high 
diagnostic power. For [11C]MET a sensitivity between 75 and 90% and a specificity 
between 72 and 92% for the detection of malignant transformation and its 
distinction to RN was demonstrated in different studies [137, 144, 146]. For 
[18F]FET a positive predictive value of 84%, a sensitivity of 82% and a specificity 
100% for the differentiation between tumor recurrence and reactive changes was 
reported [100, 114]. To improve the accuracy of [18F]FET PET scans in the 
discrimination of tumor recurrence from posttherapeutic changes, Rachinger et al. 
analyzed the maximal standardized uptake value (SUVmax) for the slice with the 
highest FET uptake in the area with suspected tumor. A sensitivity of 100% and a 
specificity of 93% could be achieved for [18F]FET PET, which was significantly 
higher compared to the results of conventional MRI with 94% and 50%, 
respectively [115]. Nevertheless, the damage of the blood-brain barrier could 
possibly be a source of misinterpretation, as the amino acid uptake might be 
governed by alteration of the blood brain barrier, causing an increased passive 
influx [119]. La Fougere conclude that although amino acid PET is not precise 
enough to replace histological verification yet, it provides additional information 
that might be helpful in the detection of glioma recurrence as well as to monitor 
new treatment modalities like antiangiogenic therapies [83]. 
CT today has widely been replaced by MRI as the imaging modality of choice in 
the initial assessment of intracranial lesions. Moreover, in recent years SPECT, 
using various isotopes to detect abnormalities in the blood brain barrier, shows 
promising results in the diagnosis of different types of intracranial lesions, the 
determination of residual or recurrent tumor and the assessment of response to 
treatment [135]. Currently utilized tracers are 201Thallium (201Tl), 
99mtechnetium (99mTc)-glucoheptonic-acid, 123iodine (123I)-alpha-methyl-tyrosine 
and 99mTchexakis-2-methoxyisobutylisonitrile (99mTc-MIBI). These radionuclides 
possess longer half-lives than most PET tracers (e.g. 13,2 h for 123I and 6 h for 
99mTc, compared to 110 min for 18F and 20 min for 11C), which offers advantages 
like a facilitated chemical synthesis [167]. Generally a high tracer uptake in 
SPECT indicates PD, whereas a negative SPECT result suggests the absence of 
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active tumor growth [31]. As Tie et al. state, in their study 201Tl-SPECT provided a 
superior diagnostic accuracy to conventional MRI and could also serve as a 
potential prognostic tool, as low tracer uptake was reflected in a significantly 
longer post imaging survival time [139]. In the last decade many studies have 
been focusing on this topic. While 201Tl offers a 100% specificity and sensitivity in 
the range of 83-100% in distinguishing RN from PD [30, 56, 139], 99mTc and 123I 
showed comparable results trying to identify tumor recurrence with an accuracy of 
93 and 96%, respectively [14, 112]. 99mTc-MIBI also has been investigated in 
various studies to detect recurrence with acceptable results; presenting a 
sensitivity of 93 and 89% and a specificity that was little lower with 83 and 83% 
[87, 164]. As Caroline and Rosenthal point out, the major advantage of Thallium is 
its exclusive uptake in pathologic tissue and not in healthy tissue, as it is found 
with other tracers. Nevertheless, certain limitations, like spatial resolution and low 
energy photon emission, are restricting the administration dose [15, 31]. 
Technetium on the other hand is not restricted by these limitations, but shows 
deficits in image interpretation, as the choroid plexus and the temporalis and 
extraocular muscles demonstrate an intense physiologic tracer uptake [15].  
Two studies cited by Caroline and Rosenthal suggest that the combination of 
imaging methods might offer additional benefits detecting tumor recurrence. 
Gomez et al. could demonstrate in 2008 that combined 201Tl -SPECT and MRI 
were more sensitive (97%) than the combination of 18F-FDG PET and MRI (83%) 
[56]. Van Laere et al. proposed in 2005 that the use of [18F]FET PET combined 
with [11C]MET presented higher accuracy (83%) than using each one of them 
solely (80 and 73%) [146]. 
As these results show, there is still potential for improvement and the need for 
innovative ideas, as proposed by us, to assess the development of this disease 
more precisely, without burdening the patients with additional investigations and 
the hospitals with additional costs. 
Discussion 
100 
5.2.2 Imaging Phenomena: Pseudoprogression, Radiation Necrosis and 
Pseudoresponse 
Different treatment induced radiologic phenomena have hampered the work of 
radiologists and oncologists in interpreting images of intracranial lesions, 
especially the so called pseudoprogression (PP), radiation necrosis (RN) and 
pseudoresponse (PR). 
The term “Pseudoprogression” was originally inaugurated by Hoffman et al. in 
1979 [66] and characterizes treatment-induced imaging changes, occurring 
particularly in the period immediately following completion of RT [19]. It is believed 
that PP is caused by cytotoxic effects of chemotherapy and radiation, resulting in a 
subacute inflammatory response with abnormal vessel permeability and local 
edema. Up to 20% of the patients develop this phenomenon after treatment with 
TMZ chemoradiotherapy. It is believed that in the case of PP the patients often 
remain asymptomatic and the image changes decrease in size or normalize 
without additional interventions [26]. De Witt et al. revisited this phenomenon in the 
year 2004 in patients with newly diagnosed GBM treated with RT and with or 
without carmustine [43]. They showed that from all patients presenting with 
disease progression immediately after RT (28% to 51%), more than half (28% to 
33%; 9% to 14% of the total) subsequently either improved or demonstrated stable 
brain imaging. 
With the aim to identify certain characteristics, Chamberlain et al. analyzed this 
phenomenon with the principles of pathology [33]: Within all patients 50% showed 
progressive disease of which 50% were treated surgically (25% of the total). 
Remarkably, half of the re-operated patients (14% of the total) displayed treatment 
injury without identifiable glioblastoma tissue. Hence, PP was characterized as to 
appear mainly (approximately 58%) within the first 3 months after completing RT 
plus TMZ. Nevertheless, this cannot be interpreted as an average course of 
disease, as only one third of all patients have been reinvestigated within the first 3 
month after the completion of RT plus TMZ. Taal et al. investigated the incidence 
of early PP and its clinical features, based on the MacDonald Criteria, by reviewing 
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a cohort of patients with newly diagnosed malignant gliomas, who were treated 
with RT plus concomitant and adjuvant TMZ [136]. In this retrospective study 36 of 
85 patients (42% of the total) exhibited early disease progression in the first follow-
up scan 4 weeks after the end of RT. PP was diagnosed in 18 of these 36 patients 
(50%). Brandes et al. analyzed the phenomenon with regard to the tumor’s MGMT 
promotor methylation status [25]. In 103 reviewed patients 36 (35%) were found 
with MGMT promotor methylation. Of the 50 patients who showed early 
progression at the first MRI scan subsequently 32 were classified with PP. Within 
23 patients with methylated MGMT promotor and early disease progression 21 
(91%) were recorded as PP. The detection of PP and of MGMT status both 
significantly influenced survival. 
Commenting on Brandes et al. study from 2008 and referring to the mentioned 
studies, M.C. Chamberlain concludes that PP is characterized by signs of early 
disease recurrence seen on Gd-MR scans immediately post-RT plus TMZ with 
improvement or stabilization after 2 months [32]. 
Radiation Necrosis was first reported in 1930 in a case of basal cell epithelioma 
[51] and has been initially described as a side effect following radiation therapy of 
extracranial malignancies [55]. It can occur between a few months and many 
years post-irradiation. Most cases present within a six-month to two-year period, 
the time during which tumor recurrence is also most frequent [10]. It most often 
can be found around blood vessels within the white matter. Typical histopathologic 
findings in the vessel walls are fibrinoid necrosis followed by hyalinization with 
consecutive luminal narrowing caused by wall thickening. Surrounding 
perivascular coagulative necrosis have the potential to coalesce, forming large 
areas of parenchymal necrosis with subsequent deposition of mineral salts (ie, 
dystrophic calcification). Additionally, abnormal telangiectasias, as well as focal 
and diffuse demyelination of the white matter, can be observed [81]. For a 
standard therapy course with a cumulative dose of 60 Gy and 1,8-2 Gy per single 
dose an incidence of 3-5% has been shown [107]. If higher dosages or additional 
treatments as brachytherapy, experimental chemotherapy protocols or stereotactic 
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RT following standard RT are applied, the chance to develop RN can rise up to 
40% [107, 121]. Moreover, Chamberlain et al. in 2007 presented a study of 51 
patients who received the standard of care for patients with newly diagnosed GBM 
(TMZ given concurrently with RT followed by 6 monthly cycles of TMZ), which 
indicates that daily administration of TMZ may represent a strong radio-sensitizing 
regimen. They reported that from 15 patients who underwent re-operation within 6 
months of completion of RT for suspected progressive GBM almost 50% (7 
patients) showed histologically confirmed necrosis without evidence of active 
tumor (14% of the whole study group) [33]. These results support the assumption 
that the RN and PP cannot be separated clearly and that PP might just be a mild, 
self-limited type of therapy-induced necrosis. Usually the radiation-related injury is 
placed around the initial tumor bed, but can also occur in other areas included in 
the radiation field [10]. As the clinical symptoms are very inconsistent they easily 
can mimic tumor recurrence. Most commonly observed are clinical signs as 
headache, seizures, personality changes and neurologic deficits [110]. 
Another radiologic phenomenon caused by the use of antiangiogenetic drugs was 
named by the term Pseudoresponse or Pseudoregression. Because 
hypervascularisation by the help of VEGF plays a critical role in the genesis of 
malignant gliomas, recent approaches include antiangiogenetic agents, especially 
those targeting VEGF, such as bevacizumab, and the VEGF receptor, such as 
cediranib. The use of such agents like the monoclonal antibody bevacizumab, 
which binds VEGF and by that is able to normalize the tumor vasculature, can 
cause marked decrease in contrast enhancement as early as 1 to 2 days after 
initiation of therapy and commonly result in high radiologic response rates of 25% 
to 60%, a rate that was never documented before [21, 52, 79, 148]. However, the 
conclusion of a tumor regression appears to be doubtful. Even if the imaging 
implies a tumor regression the effect on overall survival is limited, which suggests 
that these changes may not correlate with actual tumor regression. The clinical 
significance of this phenomenon was shown in 2010 by Wick et al., who 
highlighted the discrepancy between high response rate (measured by MacDonald 
Criteria) and the comparatively modest survival benefit [160]. The apparent 
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response mostly is due to normalization of the tumors blood-brain barrier, rather 
than to a real anti-tumorous effect. It is common that normalization like that might 
cause decrease of perifocal edema, which consequently leads to neurological 
improvements [20, 24].  
This effect proves another aspect where the MacDonald Criteria fail to be 
adequate, namely in not taking nonenhancing tumors into account [159]. Norden 
et al. even imply that in this context progression-free-survival might be an 
inappropriate endpoint for phase II trials [105]. 
As described in 5.1, using the DoctorEye software is an elegant way of analyzing 
changes in the texture of routine MRI scans. There is a chance that by testing our 
method on proven cases of PP, RN and PR a new diagnostic procedure could be 
developed to address these radiologic issues, as implied in chapters 4.2.3 and 
4.2.5. This procedure would be based on the use of DoctorEye, the incorporation 
of all four MR sequences into the diagnosis process and the combined 
interpretation of SI-histograms and specific volume-developments, which is 
described in the following chapter. 
5.2.3 Volumetric Measurements 
The approximation of tumor size is often used as an end point in clinical trials of 
oncology therapy. Traditionally it has been assessed by measuring the cross-
sectional area, as suggested by the McDonald-criteria, which is calculated as the 
product of the lesion’s longest diameter and its longest perpendicular diameter 
[96]. Especially in our study these criteria appeared inappropriate, as they bear a 
high risk of error due to the typically irregular shaped GBM lesions and the 
regularly included necrotic areas. Therefore, we decided to determine tumor-
volume measurement as described in chapter 3.3.5 Statistical Analysis. Since we 
did not only investigate our segmentations of the whole tumor, but also of the 
subunits active tumor, necrotic area and edema, we were able to calculate the 
specific volume for each of these single qualities and compare them with each 
other and the whole lesion over the course of time. This allowed us to evaluate the 
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volume-development from different patients, different tumor qualities and 
sequences at the time of diagnosis and during follow-up. Especially in the 
evaluation of the follow-up data this gain of presumably objective, complementary 
information might be of great value. The precise knowledge of the volumetric 
development of active tumor, necrosis and edema could be a helpful tool in the 
explanation of individual symptoms caused by the lesion, in the assessment of 
response or reaction to different treatment strategies and in the estimation of 
prognosis and survival. In addition this approach could provide a new end point in 
clinical trials in oncology. Nevertheless, to prove the reliability and the usefulness 
as a prognostic marker, further validation has to be done.  
In the study published by Ertl-Wagner et al. in 2009 the authors assessed the 
reliability of tumor volume estimation by two semi-automatic segmentation 
methods and a manual method, comparing the results of 16 independent readers. 
They could show that semi-automated software systems are more reliable than 
manual measurements [48]. Challenging the classical cross-sectional volume 
estimation on T1 postcontrast images, proposed by the McDonald criteria, Wang 
et al. investigated the value of software supported volume measurement in high 
resolution 3D MRI [149]. Even though volumetric measurement allows a more 
accurate estimation of irregular shaped tumors, the results of cross sectional area 
measurement were almost comparable and revealed a high correlation. 
Nevertheless, Wang et al. underline that cross sectional area measurement 
retains the already mentioned limitations and that volumetric measurements might 
be more accurate, as confirmed in several other studies [45, 65, 71, 129, 163], 
whereas the proposed method was much more time consuming. Even though 
tumor volume might not be a prognostic factor, as shown by Iliadis et al., it still is 
of important oncologic value [71]. 
5.2.4 Tumor Modeling 
On the threshold of a new era of personalized medicine, the use of in silico cancer 
modeling is gaining more and more importance [44]. Nevertheless, just a few 
groups investigate simulation models based on MR technologies for the prediction 
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of tumor response in GBM [37, 150, 169]. Chen et al. could show in 2010 that 
such simulations are able to successfully predict the region of recurrence in 
glioblastoma. Precise data from imaging studies are of utmost importance to gain 
such results in silico oncology models. The better these data are the more 
accurate predictions can be achieved [130, 131]. For the validation of the models 
the analysis of segmentations from tumor images at diagnosis and during follow-
up is of utmost importance. A correlation between tumor texture and signal 
intensities in MRI expressed by histograms of signal intensities is a step forward in 
precisely differentiating between and calculating volumes of different tumor areas, 
e.g. necrotic and vital tumor. The value of such histogram data in in-silico oncology 
models and the onco-simulator is under investigation in different EU funded 
projects [6, 7]. The results of our study and our influence on the development of 
the DoctorEye software made a great contribution to the progress of these 
projects.  
5.3 Limitations and Perspectives 
To start with the limitations of our approach we had to realize, that the inter-
individual comparability of our results, i.e. from one patient to another or from one 
MRI study to another, was limited due to the still insufficient standardization of 
technical procedures in neuroimaging. For example, various diagnostic centers 
often use different MRI technology and settings. Moreover, even within the same 
center there often is a lack of standardization due to different preferences for 
operating procedures. In addition, the semiautomatic rendering we had to engage, 
proved to be very time consuming if high accuracy was required. 
On the other hand, the new methodological approach we investigated has the 
potential to provide important new information, without the need to perform 
additional investigations of the patient. Besides offering more convenience for the 
patient, this also spares time and money. Furthermore, we could gain objective 
data as a basis for the modeling of tumor growth or therapeutic response. It also 
could provide a complementary tool for objective documentation and follow-up of a 
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patient’s clinical record. As GBM exhibits a typical bimodal distribution of signal 
intensities it can be questioned whether other brain tumor entities express different 
shapes of the histogram of signal intensities as well. If shown to be so, this method 
would support a better characterization of brain tumors by MRI. 
Nevertheless, before this method can be transferred into routine clinical praxis, 
several prerequisites have to be provided, as mentioned earlier. First of all an 
improved standardization of the imaging procedures is of utmost importance as 
well as the extended validation of our results, for example by the help of PET-
scans. Finally, as human beings represent a very slow performing and potentially 
imprecise rendering device, an automatic segmentation tool definitely would 
improve the clinical applicability of the method. Therefore, with the help of our 
partners we are working on solutions for these issues. 
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Figure 38: Ethical Approval from the ‘Ärztekammer des Saarlandes’ 
Ethical Approval given by the Ethical Committee of the ‘Ärztekammer des Saarlandes’ at the 20
th
 of 
July 2010 for the ContraCancrum- (Clinically Oriented Translational Cancer Multilevel Modelling; 
project reference number: 223979; http://contracancrum.eu/) and TUMOR-Project (Transatlantic 
Tumour Model Repositories: project reference number: 247754; http://tumor-project.eu/) that were 
funded under the 7
th
 Framework Program of the European Commission.
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Universität des Saarlandes 
06/2012   Approbation als Arzt 
05/2012   Zweiter Abschnitt der Ärztlichen Prüfung (Note „gut“) 
09/2007 – 08/2008 ERASMUS Studium an der Universidad de LaLaguna, 
Spanien 
08/2007   Erster Abschnitt der Ärztlichen Prüfung (Note „gut“) 
09/2005 Beginn des Hochschulstudiums der Humanmedizin an 
der medizinischen Fakultät der Universität des 
Saarlandes 
 
Schulbildung: 
03/2005   Allgemeine Hochschulreife (Note: 1,7) 
09/1996 – 03/2005  Gutenberg-Gymnasium, Mainz 
09/1992 – 07/1996  Heinrich-Mumbächer-Grundschule, Mainz 
 
